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 provides training in HSR for career researchers and for health service professionals; 
 
 provides educational support to NHS staff in the application of the results of research; 
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The Directors of the Institute are: Professor R L Akehurst (Sheffield); 
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H Williams (Nottingham); and     
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 FOREWORD 
 
The Trent Working Group on Acute Purchasing was set up to enable purchasers to share 
research knowledge about the effectiveness and cost-effectiveness of acute service 
interventions and determine collectively their purchasing policy. The Group is facilitated by 
The School of Health and Related Research (ScHARR), part of the Trent Institute for Health 
Services Research, the ScHARR Support Team being led by Professor Ron Akehurst and 
Dr Nick Payne, Consultant Senior Lecturer in Public Health Medicine. 
 
The process employed operates as follows. A list of topics for consideration by the Group is 
recommended by the purchasing authorities in Trent and approved by the Health Authority 
And Trust Chief Executives (HATCH) and the Trent Development and Evaluation Committee 
(DEC). A public health consultant from a purchasing authority leads on each topic assisted 
by a support team from ScHARR, which provides help including literature searching, health 
economics and modelling. A seminar is led by the public health consultant on the particular 
intervention where purchasers and provider clinicians consider research evidence and agree 
provisional recommendations on purchasing policy. The guidance emanating from the 
seminars is reflected in this series of Guidance Notes which have been reviewed by the 
Trent DEC, chaired by Professor Sir David Hull. 
 
In order to share the work on reviewing the effectiveness and cost-effectiveness of clinical 
interventions, The Trent Institute’s Working Group on Acute Purchasing has joined a wider 
collaboration, InterTASC, with units in other regions. These are: The Wessex Institute for 
Health Research and Development and The University of Birmingham Department of Public 
Health and Epidemiology. 
 
 
 
 
 
 
 
Professor R L Akehurst 
Chairman, Trent Working Group on Acute Purchasing 
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SUMMARY 
 
Severe spasticity is a significant problem for many patients with spinal cord injury, multiple 
sclerosis and cerebral palsy, causing a loss of independence and mobility, pain, sleep 
problems, difficulties in nursing care and aggravating other problems such as skin breakdown 
and urinary incontinence. 
 
Description of Proposed Service 
Continuous Intrathecal Baclofen Infusion (CIBI) is used in the treatment of patients whose 
spasticity is refractory to other treatments for the management of spasticity (including physical 
therapies and oral treatments), or for patients who experience unacceptable side-effects with 
oral drug therapy. 
 
Although CIBI has been shown to reduce severe spasticity of spinal origin and to a lesser 
degree spasticity of cerebral origin, its effect on patient function and quality of life is less clear.    
 
Number and Quality of Studies and Direction of Evidence 
Studies which reported outcomes related to function or quality of life were identified and 
reviewed. The majority of these were small, open, uncontrolled, follow-up studies with 
subjective outcome measures. 
 
Summary of Benefits 
Functional improvements included improvements in ability to sit out of bed or to sit more 
comfortably in a wheelchair, improved ease of nursing care and moderate improvements in 
activities of daily living.   
  
The extent of benefit is likely to be greatest in those with the most severe restriction in mobility.  
For example, around 70% of bed-bound patients may become able to sit out of bed and 90% of 
patients who find it difficult to sit in wheelchairs because of severe spasticity may be able to sit 
much more comfortably. Wheelchair users who already have a reasonable degree of function 
may experience moderate improvements in ability to perform activities of daily living, but they 
are likely to continue to need help with most activities.  The effect on patients who are already 
ambulatory has not been researched adequately, but the available evidence suggests that 
around 30% of such patients may show moderate improvements in their ability to walk and in 
around 10% of patients walking may deteriorate.  
 
Improvements in ease of nursing care will occur with most patients, although the extent of 
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improvement has not been quantified. Nursing care may be reduced greatly by improvements 
in skin integrity and the healing of chronic decubital ulcers.  Patients who require help in 
dressing are likely to need less help, but it is unlikely that they will become independent. Some 
patients may no longer need help feeding themselves. It has been reported that a few patients 
have been able to live in community settings, with support.  
 
Approximately 90% of patients with spasm related pain may benefit from a reduction in pain, 
although few studies reported objective pain measures. Approximately 82% of patients with 
urinary problems showed some improvements, including decreased nocturia, ability to self-
catheterise and becoming continent between catheters.  
 
Minor complications are not uncommon, but major complications are rare.  Improvements in 
pump design and experience in their use are thought to have reduced complication rates. 
 
Costs/QALY 
The cost of the pump and implantation procedure is estimated at around £11,800, with further 
annual costs of £500 - £900 for follow-up and refill. The battery life of the pump is around 5-7 
years, with a further procedure required after this time. 
 
No studies reported improvements in quality of life in terms of standard quality of life measures 
(QoL), thus making conventional estimates of cost-utility impossible. Use of threshold analysis 
suggested that, assuming five years of benefit are obtained, a benefit of around 0.16 quality 
adjusted life years (QALY)s would equate to a cost-utility ratio of £20,000.  This is in the same 
range of cost-effectiveness as interventions such as home haemodialysis, coronary artery 
bypass graft (CABG) or continuous ambulatory peritoneal dialysis (CAPD). Clinical opinion and 
Index of Health Related Quality of Life (IHQL) analysis suggested this scale of QoL 
improvement to be realised.  
 
Moreover, the high initial cost of CIBI implantation could be offset substantially by reductions in 
pressure sores, other admissions related to spasticity, orthopaedic procedures and reductions 
in requirements for orthoses or other aids and adaptations. 
 
The report identifies a number of possible options for purchasers.  In all options CIBI should be 
administered only within the context of an appropriately resourced and organised service, 
including an appropriately trained multi-disciplinary team with an ability to provide good follow-
up care.  The options recommend the need for further research at least in some patient groups.  
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ABBREVIATIONS 
 
ABI Acute Brain Injury 
ADL Activities of Daily Living 
CIBI  Continuous Intrathecal Baclofen Infusion 
CNS Central Nervous System 
CP  Cerebral Palsy 
CSF Cerebrospinal Fluid 
EMG Electro Myography 
IHQL Index of Health Related Quality of Life 
MS  Multiple Sclerosis  
PICU Paediatric Intensive Care Unit 
QALY Quality Adjusted Life Year 
QoL Quality of Life 
SCI Spinal Cord Injury 
SDR Selective Dorsal Rhizotomy 
TBI Traumatic Brain Injury 
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1. AIMS OF THE REVIEW  
 
Spasticity has been defined as 'a motor disorder characterised by velocity-dependent 
increase in the tonic stretch reflex (muscle tone) with exaggerated tendon jerks resulting 
from hyperexcitability of the stretch reflexes, as one component of the upper motor neurone 
syndrome'.
1
 Increased tone and spasms reduce a patient's mobility and independence and 
interfere with activities of daily living, continence and sleep patterns. Spasticity may also be 
associated with significant pain, skin breakdown, contractures, sleep disorders and 
dyspnoea as well as making transfers more difficult. Spasticity that is not effectively 
managed can lead to severe disability and loss of independence.
2,3,4
 
  
Spasticity is a significant problem for the majority of patients with multiple sclerosis (MS), 
spinal cord injury (SCI)
4,3
 cerebral palsy (CP) and acute brain injury (ABI). It is complex, but 
can be broadly defined into two causes, cerebral lesions and spinal lesions. Spasticity 
relating to cerebral lesions may be more complex and complicated by other motor disorders. 
 
Most patients with mild to moderate spasticity can be managed effectively with combinations 
of physical therapies or oral medication.
5
 However, a significant number of patients with 
more severe or generalised spasticity experience unacceptable side-effects or fail to 
improve with conventional oral drug therapy.
6
  Increasingly, Botulinum Toxin is being used to 
treat spasticity in individual muscle groups, but cannot be used for general spasticity. Prior 
to the development of implantable drug delivery systems, the only alternative for alleviation 
of severe generalised spasticity was through destructive, irreversible surgical or neurolytic 
procedures. These are often considered unacceptable alternatives by patients and doctors
2
 
and, indeed, are rarely performed within the UK. However, the use of Continuous Intrathecal 
Baclofen Infusion (CIBI) now offers an alternative to patients with intractable spasticity 
refractory to more conservative management methods.  
 
The use of baclofen as an oral treatment for spasticity is well established. However, 
penetration into the cerebrospinal fluid (CSF) is poor with oral administration, so high doses 
may be needed to achieve a therapeutic response. These high doses can result in 
unacceptable side-effects.
7
 The administration of the drug intrathecally (directly into the 
CSF) has been shown to be effective in reducing spasticity in patients with severe spasticity, 
using concentrations of the drug of less than one hundredth of those used orally.
8
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This technique has the attraction of allowing a gradual increase in the rate of infusion until 
the appropriate level of spasticity control is achieved. Some patients need some residual 
spasticity, for example, in leg extensor muscles to aid standing. The technique is, thus, 
more acceptable to many patients than irreversible destructive surgery. 
 
The technique is now being used to treat patients with SCI and MS and is being considered 
increasingly in the UK for some children with CP in conjunction with the conventional 
treatments of physiotherapy and orthoses. 
 
Uncertainty surrounding the benefits and complications associated with intrathecal baclofen, 
along with the considerable costs of pump implantation, has limited the extent to which the 
procedure is being used within the UK. 
 
The effects of CIBI are difficult to quantify, as improvements in function are highly 
individualised due to the differing expectations and experiences of each patient. However, a 
large number of case reports and small trials reporting the benefits and complications 
associated with the procedure have been published since the benefits of the intervention 
were first reported in 1984.
9
 The treatment has been reported to improve the function and 
quality of life of many carefully selected patients, although improvements have not been 
systematically reported. However, there are a number of concerns currently limiting the 
extent to which the pump is being used within the UK. The cost of providing a patient with 
intrathecal baclofen is considerable; the pump itself costs around £5,800 with significant 
additional resources for the implantation procedure and follow-up for refill. Also, many 
complications associated with the implantation have been reported, notably concerning 
problems with the pump, risk of infection and problems with the catheter. The likelihood of 
experiencing complications appears to vary considerably depending upon the experience of 
the clinician and the type of pump used. Recent experience abroad, especially in North 
America, has reduced the rate of complications leading to pump removal to an acceptable 
5% of procedures.
10
  
 
Uncertainty surrounding the benefits and complications associated with intrathecal baclofen, 
along with the considerable costs of pump implantation, have limited the extent to which the 
procedure is being used within the UK. Thus, there are a number of patients who are not yet 
receiving the treatment who potentially could benefit from doing so. 
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The purpose of this Guidance Note is to identify and review the evidence-base for the use of 
intrathecal baclofen in the treatment of spasticity and to outline the potential cost 
implications of providing the treatment for all patients who may benefit. 
 
2. DESCRIPTION OF UNDERLYING DISEASE 
 
2.1 CEREBRAL PALSY 
 
Cerebral spasticity in children (aged 18 or under) is largely due to cerebral palsy, with 
acquired encephalopathy such as head injury accounting for a small number. Cerebral palsy 
is present at birth or soon after and is the name given to a variety of conditions causing non-
progressive damage to the developing brain, causing mainly but not exclusively, motor 
problems such as spasticity. Cerebral Palsy occurs in 2-3/1000 children, around half of 
whom have generalised spasticity. 
 
Quadriplegia (loss of movement and sensation in both the arms and legs) accounts for 
around only 7% of CP, but the severity of the condition leads to considerable distress both in 
the child and his/her carers, and care is very expensive. In these patients CIBI has the 
potential to lead to improvements in nursing care, reductions in hip dislocation and 
reductions in the onset of scoliosis. 
 
Children with diplegic CP (loss of movement and sensation in corresponding limbs on both 
sides of the body) account for 44% of those with CP and are usually able to walk, even if 
only a little and with aids. Around the age of eight years, however, their mobility fails to 
improve and often subsequently deteriorates, leading in some cases to wheelchair 
confinement.
11
 This is due partly to an increasing mismatch between weight and strength, 
but also to muscle contractures developing as a result of spasticity. Orthopaedic surgery is 
needed for contractures to elongate the muscle at the tendons and, increasingly, all muscles 
are operated upon together - so called multilevel surgery, usually around the plateau 
stage.
11
 
 
In these patients, CIBI may have the potential to improve mobility, reduce spasticity and 
defer the onset of muscle contractures, in some cases avoiding the need for such extensive 
orthopaedic surgery. 
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It should be remembered, however, that any improvement due to spasticity reduction would 
only be relative, as CP involves other motor problems including weakness, poor co-
ordination and immature movement patterns.  
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2.2 MULTIPLE SCLEROSIS 
 
MS is characterised by an autoimmune process within the central nervous system (CNS) 
resulting in demyelination with secondary axonal loss. The primary trigger or triggers are not 
known. There are foci of inflammatory cell infiltration around venules predominantly in peri-
ventricular white matter, called plaques. The pathological changes are progressive whilst the 
clinical picture is usually relapsing and remitting at first, and later becoming secondarily 
progressive.  
 
The clinical pattern is both variable in severity and unpredictable. People with MS develop a 
range of symptoms and signs including fatigue, memory and attention difficulties, bowel and 
bladder problems, weakness, numbness, pain and increased muscle stiffness (increased 
tone or spasticity). People with young age at onset and sensory symptoms do relatively well 
whilst those with primary progressive MS have a poor prognosis. Approximately one third 
will need assistance to walk, or be dependent within 15 years of diagnosis.
12,13,14
 
 
The prevalence of MS in the UK is around 100 in 100,000,
15,16
 thus, within an average health 
district of 500,000 there will be 500 people with MS of whom approximately 160-180 will 
have significant disability. 
 
Increased tone or spasticity may be important contributors to disability, causing pain, 
difficulty in walking and transferring, and cause significant problems in the management of 
perineal hygiene. It may prevent comfort with seating, predispose to pressure sores and 
cause difficulty with transfers as the patients adopt an extensor posture. Tone management 
should ideally be multi-disciplinary starting with the prevention of unpleasant and painful 
stimuli and a stretching programme and progressing to adequate trials of oral therapy. Focal 
spasticity may be treated adequately with motor point blocks using botulinum, and phenol 
nerve blocks. 
 
The group of MS patients most likely to benefit from CIBI is that with non-focal spasticity and 
spasms unresponsive to conventional oral treatment including an adequate trial of baclofen, 
dantrolene, nocturnal diazepam and tizanidine.
17,18
 In general, this group is unable to walk, 
but patients are able to use powered or self propelled wheelchairs. No studies have yet 
identified the proportion of MS patients who fall into this group, but it is estimated that 
perhaps 3-4% of the MS population could benefit, that is 15 to 20 per health district of 
500,000 population. 
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2.3 SPINAL CORD INJURY 
 
Spinal cord injury (SCI) occurs as a result of road traffic accidents, violence, falls, diving 
accidents and work or sports related injuries. Patients are predominantly males in the 16-30 
year age group. The majority of SCI patients will expect a normal life span. Around 55% of 
SCI patients will be affected by paraplegia (loss of movement and sensation in the lower 
body) while 44% are affected by quadriplegia (loss of movement and sensation in both the 
arms and legs) (paralysis website - http://paralysis.apacure.org/progress/facts.html). 
  
Spasticity has been reported to develop within one year of injury in 67% of patients
19
. Soni
20
 
estimates that around 5-10% of SCI patients will require intrathecal drug delivery systems to 
treat their excessive spasticity. 
 
2.4 ACUTE BRAIN INJURY 
 
Acute brain Injury (ABI) due to traumatic brain injury (TBI), hypoxic brain injury or trauma is 
a further cause of cerebral spasticity which has been treated with CIBI.  
 
2.5 SIZE OF PROBLEM IN AN AVERAGE HEALTH AUTHORITY 
 
Table 1 provides an indication of the number of prevalent and incident cases in a health 
authority (HA) of 500,000 population. 
 
Table 1 Estimated Incidence and Prevalence of Spasticity In Conditions 
Potentially Amenable to Treatment with CIBI 
 
Disease 
Area 
Incidence 
per 
100,000 
per year 
Prevalence 
per  
100,000 
% Who May 
be 
Considered 
for CIBI 
Prevalent 
Cases who may 
Benefit from 
CIBI in a HA of 
500,000 
Incident Cases 
who may Benefit 
from CIBI in a 
HA of 500,000 
per annum 
SCI  1.7
21
    72
22
 5-10%
20
  18 - 36  0.4 - 0.8 
CP 2.6*  50 10%  25
†
  1.3
†
 
MS      3.5  100
16
 3-4%  15 - 20  1-1.3  
Total     58 - 81  2.7 – 3.4 
 
 10 
 
* Based on CP birth rate of 2 per 1,000 and overall birth rate of 1,300 per 100,000 population.
23
 
† 
These figures relate mainly to severe quadriplegic and diplegic CP with limited mobility. If CIBI were considered for those with 
mild diplegic CP also, then the prevalent cases and incident cases could be doubled. 
 
Although these analyses are extremely approximate, they suggest that there may be a large 
'backlog' of prevalent cases which could potentially benefit, but that at steady state around 
three procedures per year might be expected in each district. 
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3. CURRENT SERVICE PROVISION 
  
The use of CIBI is not standard in the UK and there are a small number of centres which 
have set up services for the use of CIBI. Many health authorities are currently not funding 
the treatment for patients with cerebral palsy due to uncertainty surrounding the benefits of 
the intervention. To date, a small number of children with cerebral palsy have received the 
treatment in England and Wales. The Trent regional centre for SCI (The Spinal Cord Injuries 
Unit, Northern General Hospital, Sheffield) sees around 100 new patients per annum. 
Around 36 intrathecal baclofen pumps have been implanted within the past six years, the 
majority of patients having had SCI, but only a few having MS. 
 
In 1998, approximately 200 patients in Britain were implanted with pumps for intrathecal 
baclofen (Medtronic). Approximately 60% were SCI patients, 30% had MS and the 
remaining 10% had an underlying cause of spasticity due to other causes, such as CP, 
traumatic brain injury and metabolic disorders.
24
 
 
3.1 CURRENT TREATMENT OPTIONS FOR THE MANAGEMENT OF SPASTICITY 
 
The management of spasticity for all patients, regardless of the underlying cause, follows a 
rational treatment plan, starting with the most conservative therapy and advancing as 
needed to a more invasive approach. Once patients begin to require the more aggressive 
methods, then the cause and degree of the spasticity, generalised or local, has an effect on 
which treatment is most beneficial. 
 
3.1.1 Initial Treatments 
 
Initial attention should be paid to eliminating noxious or external stimuli which could 
encourage the development of, or exacerbate, spasticity. This is followed by a routine of 
passive range-of-motion exercises, including physiotherapy, occupational therapy, 
hydrotherapy, applications of heat and ice and various physical interventions.  
 
3.1.2 Oral Treatments 
 
Once this line of treatment has been exhausted, oral drug therapy is considered. Single 
doses or combinations of a number of drugs may be tried, including baclofen (Lioresal), 
diazepam, dantrolene sodium (Dantrium), tizanidine and benzodiazepines. Baclofen is the 
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drug of choice for spinal cord spasticity, but 25-30% of SCI patients still fail to respond.
25
 
The major drawbacks with oral drug therapy are the side-effects. Many patients find them 
intolerable when the medications are given at the dosage level required to be effective. The 
main side-effects are lethargy, weakness, somnolence, dizziness and mental confusion, 
which is reported to occur in approximately 10-20% of patients.
25
 Other side-effects include 
hallucinations, hypotonia and ataxia. 
 
3.1.3 Botulinum Toxin 
 
Intramuscular injection of botulinum toxin to reduce spasticity has been used increasingly in 
the past five years in adults and children suffering from MS,
26
 stroke
27
 and CP.
28
 It can easily 
be given as an out-patient procedure, sometimes with mild sedation. However, because of 
the limited amount that can be given safely at one time, only a small number of muscles can 
be treated on a 4-6 monthly basis. Its use, therefore, tends to be restricted to certain muscle 
groups, for example the hip adductors in quadriplegic CP. Knowledge of this technique is 
still incomplete, especially the benefits from repeated use as some patients may develop a 
resistance to botulinum.
29
 
 
Apart from reducing spasticity, weakness is also created, although this is rarely a practical 
problem. There is a maximal total dose according to body weight for each course of 
treatment, beyond which toxin escapes into the systemic circulation in significant amounts to 
cause general fatigue. This limits the number of muscles which can be treated at any one 
time (four in the lower limb or eight in the upper limb) and current practice dictates a 
minimum of around four months between treatments to avoid resistance due to antibody 
formation.
30
 
 
The major indications for botulinum are in the relief of spasticity in the calves in children with 
hemiplegic CP (loss of movement and sensation in the right or left half of the body) and the 
calves, hamstrings and hip adductors in diplegics. The plan, as for other anti-spasticity 
treatments, is to defer the time for orthopaedic surgery, and perhaps avoid some 
procedures. Botulinum can also be used to good effect in quadriplegics, especially in the hip 
adductors,
31
 although it has not yet been established as to whether this is sufficient to avoid 
hip dislocation. It is likely to become established as a primary treatment in many children 
with CP. However, it is not usually considered for SCI patients as the treatment is not really 
appropriate in generalised spasticity. 
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3.1.4 Selective Dorsal Rhizotomy  
 
This technique has been popular abroad in reducing cerebral spasticity in children but 
continues to be less popular in the UK.
32
 A laminotomy is performed (L1 - L5) and selective 
dorsal roots are cut under the guidance of intraoperative electro-myography (EMG), 
involving the sacral roots, but avoiding those affecting the bladder.
33
 Dramatic reductions in 
spasticity can result, leading to improvements in gait in diplegics,
34
 although most patients 
still need orthopaedic surgery within four years.
35
 Post-operative complications still occur in 
17% of procedures,
36
 although most are temporary. Abnormal perineal sensation can 
persist, and spinal complications also occur,
31
 but probably will be reduced by the modern 
practice of replacing the boney arches after rhizotomy. Its use in quadriplegics already at 
risk of scoliosis remains contentious. 
 
The major debate around Selective Dorsal Rhizotomy (SDR) concerns whether documented 
functional benefits result from the spasticity reduction it produces, or simply the intensive 
physiotherapy needed for a year or more afterwards. Three recent blinded and controlled 
trials have been unable to sort this out. Each compared two matched groups of diplegic 
children, one receiving SDR and intensive physiotherapy and the other intensive 
physiotherapy alone, measuring outcome with a validated scale of motor function in 
children.
37
 Two studies showed a significant improvement in the SDR group up to one 
year,
38,39
 but the third showed no difference at two years.
40
 The indications for SDR in the 
UK remain uncertain, although the invasiveness of the procedure, together with its 
complications, continue to make it unpopular with many clinicians here, despite it being 
probably cheaper overall than CIBI.
41
 
 
3.1.5 Therapeutic Nerve Blocks 
 
Therapeutic nerve blocks tend to be used to treat MS or SCI patients. Nerve blocks can 
either be administered peripherally, in order to manage localised spasticity, or be given to 
motor points, known as motor point blocks, which are areas of muscle which produce 
maximum contractions when stimulated. Passive range of movement exercises, splinting 
and devices to maintain proper joint positioning are recommended in conjunction with nerve 
block therapy. 
 
Intraneural or perineural 2-5% phenol injection is one of the most common types of 
peripheral nerve block. Phenol acts by protein denaturation of nerve fibres. In 
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concentrations of <1%, phenol has local anaesthetic effects which are fully reversible. 
Percutaneous phenol injections are relatively simple procedures, but a thorough knowledge 
of peipheral neuroanatomy, kinesiology and electrodiagnostic techniques is essential to 
perform these procedures safely. Common sites injected are the obturator nerve in adductor 
spasticity, posterior tibial nerve for the relief of calf spasticity and ankle clonus, 
musculocutaneous nerve for elbow spasticity causing flexion deformity in hemiplegia, and 
median and ulnar nerves for wrist and finger spasticity. Alcohol is also injected locally, with 
its mechanism of action thought to be dehydration effect on nerve tissue, resulting in 
sclerosis of nerve fibres and myelin sheath destruction. 
 
For the motor point block, 5% phenol is used and effects may last for a month or for as long 
as two years. The motor points of individual muscles can be identified by the manipulation of 
a stimulating Teflon-coated needle and then destroyed by the injection. The technique is 
time consuming but effective.
42
 Motor point injections can be used on the hip adductors and 
calf muscles, which may prevent scissoring and deformity respectively. 
 
The complications of phenol or alcohol injections include post-block pain when injected into 
a mixed motor sensory nerve or due to an incomplete block. This occurs with a frequency of 
2-10%.
43
 Other complications include dysaesthesia, cardiac arrhythmia, variable duration of 
effect and incomplete recovery. 
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4. DESCRIPTION OF NEW INTERVENTION 
  
Following the standard multidisciplinary management of patients with spasticity, some 
patients whose spasticity is uncontrolled by alternative therapies may be considered suitable 
for CIBI.  
 
4.1 PRE-SCREENING ASSESSMENT 
 
If these patients fulfil selection criteria, have no contraindications to the insertion of an 
intrathecal catheter (such as anti-coagulant therapy, coagulopathy, local or systemic 
infection, anatomical abnormality of the spine) and are in agreement, then a trial of 
intrathecal baclofen may proceed.  
 
The technique is fully discussed with the patient. It will be explained that bolus test doses of 
baclofen will be given on a daily basis and that initially a temporary catheter will be inserted 
intrathecally for this procedure. Response to the bolus doses will be assessed on the 
Ashworth Scale. Informed consent is obtained from the patient before proceeding. 
 
4.2 TEST PROCEDURE 
 
An intrathecal catheter is inserted under local anaesthesia and light sedation, if necessary, 
using an aseptic technique in the operating theatre and using X-ray screening. A general 
anaesthetic is not normally required. Baclofen is given intrathecally and the patient returned 
to the ward for observation. Monitoring of vital signs and change in spasticity is undertaken 
by ward nurses and doctors trained in the identification and treatment of baclofen toxicity. 
The dose of baclofen is titrated upwards in 25 microgram per day aliquots until the patient 
responds. If the patient does not react to 100 microgrammes intrathecally he/she is 
considered not to have an adequate response and should not undergo implantation. 
Following an adequate reaction the catheter is removed. 
 
For children with CP, a general anaesthetic will be administered. While under anaesthetic, 
tests for orthopaedic problems that will contraindicate the use of CIBI are undertaken and 
used as part of the assessment of patient suitability, i.e. ankles no longer movable, knees 
unable to bend, decreased tone in lower limbs. 
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4.3 PUMP IMPLANTATION 
 
Following a positive response with a test dose and discussion of the potential benefits with 
the patients (and parent(s) in the case of children), the decision as to whether an implant 
should go ahead is made. For the implant, the patient is admitted to hospital the night before 
surgery is planned. Insertion of the pump is performed using an aseptic technique under 
general anaesthesia, radiological control and antibiotic cover. The catheter is fixed, the 
pump pocket formed and the pump prepared according to the manufacturer’s instruction 
and filled with the correct volume of baclofen. The pump is then connected to the catheter, 
inserted into the pocket and the incisions sutured. The volume of the catheter must be 
calculated accurately to ensure the correct programming of the pump. This is done by 
measuring accurately the catheter left at the end of the surgical procedure. 
 
4.4 POST-OPERATIVE MONITORING 
 
The patient is returned to the ward and undergoes routine post-operative monitoring and 
also observation for signs of baclofen overdose (light-headedness, drowsiness, 
unconsciousness, infusion, depressed respiration, coma). Nurses on the ward should be 
fully acquainted with the programmer and should be able to perform an ‘emergency stop’ 
procedure. 
 
If no complications are experienced, the patient may be discharged after 5-10 days. 
Potential post-operative complications comprise: 
 
1. Heamatoma/seroma 
2. Infection 
3. CSF leakage. 
 
Patients will receive antibiotics two weeks post-operatively. 
 
4.5 FOLLOW-UP 
 
Following discharge from hospital, patients will require regular follow-up visits for monitoring 
and pump refills. Training of carers, hospital staff and specialised nurses is important as it 
will be these people primarily who are required to monitor the patients and observe any vital 
changes in their conditions. Specialist baclofen nurses are required for the follow-up visits 
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and pump refills after implantation. Typically, these visits take place within an out-patient 
clinic or office setting, but may take place in a rehabilitation facility or in the home of the 
patient, as transport of severely affected patients is very difficult. 
 
A protocol needs to be developed for trouble-shooting any problems and for re-filling the 
pump at appropriate time intervals. Ward nurses and junior doctors in the ward area need to 
undergo a training programme. This needs to be an ongoing programme to cover changes 
of staff. The education of GPs, out-reach nurses and district nurses should also be 
arranged. There should be senior doctor cover for emergencies. 
 
4.6 PERSONNEL AND SETTING 
 
Due to the need for follow-up and the possibility of complications, CIBI requires an 
appropriately trained multi-disciplinary team. A specialist surgical team may include a 
neurosurgeon, anaesthetist, and general surgeon for implanting the pump and attending to 
any complications, although not all three will be required. The pump should be implanted at 
a specialist centre, after which the patient should be referred to a local centre to be 
managed. Local clinicians should be involved in monitoring the pump in association with 
appropriately trained nurses. 
 
4.7 LENGTH OF TREATMENT 
 
The length of time that the treatment will be administered depends upon the nature of the 
underlying disease. For a progressive disease such as MS, the length of time CIBI will be 
beneficial will be dependent upon the progression of the disease. For other conditions such 
as SCI or CP, where life expectancy is not generally reduced or progression does not affect 
the spasticity, there is no defined limit as to how long the treatment will be required. Long-
term use of CIBI has not been reported as the intervention was only introduced in 1984. 
However, Albright has reported the successful use of CIBI in patients for over 10 years.
10
  
 
Due to limited battery life, the initial pump procedure will need to be repeated every 5-7 
years depending upon the type of pump used. The dosage of baclofen may be increased 
due to increased tolerance of the drug, but the optimal dose often levels out after one year. 
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5. METHODS 
 
A literature search of Medline, Embase, DARE and Cochrane Collaboration databases was 
carried out, using the search terms ‘Intrathecal’ and ‘Baclofen’. All abstracts identified were 
reviewed and articles requested if they met suitable criteria. 
 
5.1 RESULTS 
 
Due to the considerable yield of trials (94 studies) identified from the literature search, 
further criteria for inclusion were agreed upon. Trials and reviews on the use of intrathecal 
baclofen were considered if they investigated patients with the following conditions: cerebral 
palsy, multiple sclerosis, spinal injury, traumatic brain injury or hypoxic brain injury. Further 
inclusion criteria specified trials, which sought to measure patient outcomes in terms of: 
 
 Function; 
 Quality of life; 
 Pain; 
 Subjective patient/carer report of effectiveness; or 
 Health service use. 
 
Trials measuring the effect of intervention on the carer’s quality of life or perceived ease of 
patient care were also considered. Trials seeking only to record measurements of patient 
impairment such as the Ashworth score, spasm score or reflex score were not included. 
These measures provide some indication of the physiological effect of the intervention, but 
do not necessarily relate to improvements in function or quality of life.  
 
Further inclusion criteria specified that trials must include more than one patient and have 
an average follow-up period of at least six months. Further papers were requested if they 
reported any major complications due to the treatment.  
 
For the purpose of economic analysis, references with keywords ‘costs’ or ‘economic’ were 
also obtained. 
 
Reference lists of review articles and of the papers included in this review were also 
scanned to identify further papers. 
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A standard data form was used as the data extraction strategy to extract information from 
the relevant papers identified.  
 
5.2 QUALITY OF EVIDENCE 
 
Most studies were before-and-after observational trials. Only one employed a blinded 
randomised controlled methodology for part of the trial, and this randomised part lasted only 
13 weeks.  
 
The number of patients in most trials is small, although there are several larger trials.  
 
Many trials did not describe the methodology they had used to measure the functional 
outcomes they described, and it appeared possible that they had made qualitative 
judgements rather than used quantified measures. For example, some trials stated that, 
post-treatment, some patients were easier to care for, but gave no indication of how this had 
been assessed. A minority of trials used validated outcome measures, but other trials used 
outcomes measures which had not necessarily been demonstrated as being reliable and 
valid for the purpose.   
 
The majority of reports provided no statistical analysis.   
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6. RESULTS 
 
6.1 QUANTITY AND QUALITY OF RESEARCH AVAILABLE 
 
6.1.1  Quantity and Type of Evidence Available 
 
94 studies were identified of which 68 were excluded. The primary reasons for exclusion are 
shown in Table 2. 
 
Table 2  Exclusion of Trials 
 
Reason for Exclusion Number of Papers 
Excluded 
Reports of complications only 21 
Wrong outcomes measured 
(usually confined to Ashworth +/- spasm/reflex scores) 
17 
Case reports 9 
Health economics outcomes only (included in economics 
review) 
7 
Trial of bolus dose only 6 
Follow-up less than 6 months 6 
Preliminary reports of data presented elsewhere 2 
 
26 original studies met the criteria for inclusion in the review of effectiveness. One meta-
analysis was also used in the review of effectiveness. 
 
Only one randomised controlled trial of CIBI was identified, with a randomisation phase of 
three months. All the other trials related to the uncontrolled follow-up of patients with 
continuous intrathecal baclofen. 
 
 8 studies only included patients with spasticity of spinal origin (See Appendix A);  
 6 studies only included patients with spasticity of cerebral origin (See Appendix B); 
 12 studies either included patients with spasticity of cerebral origin and patients with 
spasticity of spinal origin, or it was not clear whether the origin of spasticity was spinal or 
cerebral in some patients (See Appendix C). 
 
 21 
 
6.1.2  Outcome Measures  
 
Most studies used either the Ashworth score,
44
 or a modified version
45
 of this to measure the 
level of spasticity. This is a five-point scale as described below. Both the original scale and 
the modified version have been shown to have good inter-rater reliability.
46,47
 
 
The Ashworth Scale: 
0. No increase in muscle tone; 
1. Slight increase in muscle tone giving a catch when the limb is moved; 
2. More marked increase in tone, but limb is easily moved; 
3. Considerable increase in tone-passive movement difficult; 
4. Limb rigid in flexion or extension (abduction/adduction). 
 
The main problem with the scale is that, although it gives an indication of the degree of 
spasticity, it gives no indication of how that spasticity affects the patient’s function or quality 
of life. 
 
The Penn spasm score is also often used in studies. This measures the frequency of 
spasms, but again provides no indication of how this affects function or quality of life. 
 
A large variety of measures relating to function or quality of life have also been used, 
however, most studies do not use any formal scales to measure these outcomes.  
 
These include: 
 
 Outcomes related to mobility e.g. ability to sit out of bed, ability to transfer, wheelchair 
mobility, ability to walk. Most studies relate to improved ability in these areas, but do not 
use any scales to quantify these improvements. 
 Activities of daily living (ADLs) – many studies mention ADLs, but do not appear to use 
any formal scales to assess these. 
 Level of nursing – many studies report on improved ease of nursing care, but do not 
quantify this. 
 Pain – several studies report decreases in pain, but do not use formal scoring systems. 
 
A few studies have used formal scores to measure function or quality of life. Scores used 
include: 
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 The Sickness Impact Profile (2 studies)
48,49,50
 
 The Functional Independence Measure (1 study)
51
 
 The Hopkins Symptom Checklist (1 study)
50
 
 The Barthel score (1 study)
52
 
 Ferrans and Powers Quality of life index
49
 
 The Functional Disability score
53
 
  
The best validated of these scores is the Sickness Impact Profile. The score aims to 
measure the impact of the patient's condition on performance (rather than on capacity for 
performance). The behaviours included are designed to represent limitations that may be 
affected by any disease. The score consists of 136 questions grouped into different areas. It 
has a physical sub-score (including ambulation, mobility, body care and movement) and 
psychological sub-score (including social interaction, alertness, emotional behaviour and 
communication). Scores are standardised and reported on a 0-100 scale. The scale is 
designed to be reported either as separate physical and psychological scores or as an 
overall score. The score has been shown to have good repeatability, inter-rater reliability, 
and validity (when compared with other scores). Its sensitivity to clinical change has varied 
in different studies. The score has been used in a wide variety of different conditions. 
 
The Functional Independence Measure (FIM), described below, is a seven point scale for 
measuring the level of independence in self-care, sphincter control, mobility, locomotion, 
communication and social cognition. 
 
1 = total assistance 5 = supervision or prior preparation 
2 = maximal assistance 6 = modified independence 
3 = moderate assistance 7 = complete independence 
4 = minimal assistance   
 
The score has been shown to have good inter-rater reliability and has been used in a wide 
variety of patient groups requiring rehabilitation. 
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6.2  EVIDENCE OF EFFECTIVENESS OF CIBI 
 
6.2.1  Meta-analysis of Intrathecal Baclofen (Creedon et al. 1997)
54
 
 
A meta-analysis of English language trials of CIBI published prior to June 1996 included 27 
studies. (490 patients, 206 spinal cord injury, 162 multiple sclerosis, 59 cerebral palsy, 64 
other causes of severe spasticity). The average patient was 36 years old, seven years post-
onset of CNS disorder, and had undergone follow-up evaluations for 18 months after 
implantation of the pump. 
 
 91% of patients who were screened had a positive response to screening; 
 92% of patients who had a pump implanted had a positive response to the pump; 
 92% of patients who had a pump implanted were still using the pump at one year follow-
up. 
 
The overall effect on Ashworth and spasm scores and the effect in different patient groups 
is shown in table 3 below. 
 
Table 3  Overall Effect on Ashworth and Spasm Scores 
 
Condition  Ashworth 
Score 
pre-CIBI  
Ashworth 
Score 
post-CIBI 
N* p Spasm 
Score 
pre-CIBI 
Spasm 
Score 
post-CIBI 
N* p 
All patients 3.9 1.6 134 <0.001 3.2 0.6 51 <0.001 
Multiple 
Sclerosis 
4.2 1.3 43 <0.001 3.2 0.4 18 <0.001 
Cerebral 
Palsy 
2.9 2.0 23 0.34 - - 0 - 
Spinal Cord 
Injury 
4.0 1.7 49 <0.001 3.4 0.8 21 <0.001 
Other  4.3 1.7 19 <0.001 3.2 0.8 11 <0.001 
* Number of patients on which estimate is based. 
 
The dosage of baclofen required to achieve spasticity reduction increased during follow-up. 
The greatest increase in dose tended to be in the first month. The average starting dose 
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was around 150 micrograms per day and after 16 months this was likely to have increased 
by 250%.  
 
The meta-analysis demonstrates that CIBI successfully reduces spasticity and spasm 
scores in around 92% of patients who have a pump implanted. The effect on spasticity in 
patients with cerebral palsy was less marked than in other patients. This needs to be 
interpreted in the light of the fact that the meta-analysis did not include many patients with 
cerebral palsy and that these patients tended to have less severe spasticity at baseline than 
other patients. 
 
Although Ashworth and spasm scores provide a useful way of monitoring spasticity they do 
not tell us anything about how spasticity affects patients’ quality of life. In view of this, and 
the fact that the meta-analysis has already summarised the data on Ashworth and spasm 
scores, the subsequent descriptions of trials included in this review do not include further 
description of the effect of CIBI on these measures. 
 
6.2.2  Likely Effects of CIBI in Patients with Spasticity of Spinal Origin 
 
Eight studies which included only patients with spasticity known to be of spinal origin fulfilled 
the inclusion criteria (160 patients in total; including 78 SCI and 65 MS). These studies are 
summarised in Appendix A. 
 
It is clear from the meta-analysis that CIBI is likely to have a dramatic effect on the degree 
of spasticity in at least 92% of patients with spasticity of spinal origin.
54
 However, the only 
randomised controlled trial of CIBI demonstrated no significant difference between placebo 
and baclofen groups in quality of life/functional measures at three months. 
 
The only large case series of CIBI in spinal spasticity is difficult to interpret, because of 
subjective outcome measures and a failure to report the numbers of patients improving.
55
 
 
The following statements concerning the effect of CIBI on function or quality of life need to 
be treated with caution as they are based on uncontrolled, open follow-up studies, mainly 
using subjective outcome measures and usually involving relatively small numbers of 
patients. 
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Patients with spinal spasticity are likely to show modest improvements on the physical 
dimension of the Sickness Impact Profile. Middel et al.
50
 reported a reduction of 41.5 to 31.5 
and Gianino et al.
49
 recorded a fall of 38.5 to 31.0. Gianino et al.
49
 also showed 
improvements on the psychosocial sub-scale (20.8 to 13.0), but no significant improvement 
at one year was shown in the study by Middel.
50
 
 
Patients with spinal spasticity who are very severely disabled are likely to benefit from 
improved ability to sit in a wheelchair and from improved nursing care.
56,53
 Patients with less 
severe disabilities may have some improvements in their ability to transfer, dress and 
mobilise.
50,53,49,56
 
 
Patients with pain related to spasticity are likely to benefit from CIBI
53,57
 and urinary 
problems may be improved.
58,59
 
 
6.2.3  Likely Effects of CIBI in Patients with Spasticity of Cerebral Origin 
 
Six studies which only included patients with spasticity of cerebral origin fulfilled the 
inclusion criteria (111 patients including 63 with cerebral palsy, the majority of the remaining 
patients had traumatic or hypoxic brain injury). These studies are summarised in Appendix 
B.  
 
The meta-analysis suggests that CIBI may be less effective in reducing spasticity in patients 
with spasticity of cerebral origin than in patients with spasticity of spinal origin. 
 
The following statements concerning effect on function or quality of life need to be treated 
with caution, because they are based on uncontrolled open follow-up studies mainly using 
subjective outcome measures and usually only involving relatively small numbers of 
patients. 
 
Bed-bound patients with cerebral spasticity are likely to benefit in terms of being able to sit 
out of bed and be pushed in a wheelchair. Ease of nursing is also likely to improve in these 
patients. Such patients are unlikely to show a measurable improvement in activities of daily 
living.
7,60
 
 
Children with severe extensor posturing are likely to find it easier to sit in a wheelchair, be 
easier to nurse and may be able to participate more in activities of daily living.
11
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Patients who are wheelchair bound may become able to walk in therapy sessions, but the 
available evidence does not suggest that they would be likely to become able to walk 
independently.
7,60,61
 Wheelchair mobility may improve, probably mainly due to improved 
upper limb function.
7,60,61
 
 
Those who can already walk independently to some extent may improve their walking ability, 
although most are unlikely to improve sufficiently to enable them to walk outside the home.
62
 
It should also be noted that walking ability may deteriorate in a proportion of ambulatory 
patients.
62
 
 
6.2.4  Likely Effect of CIBI on Different Outcome Measures 
 
Many different outcome measures were used in different studies. Outcome measures were 
often subjective. Many studies did not provide denominator data, for example they may 
report that two patients had decreased pain, but not say how many patients suffered from 
pain before treatment. Tables 4-8 have attempted to summarise outcomes related to 
mobility, activities of daily living, dependency and the need for nursing care, and other 
quality of life issues. Only studies where appropriate denominator data were provided have 
been included. Each entry also describes the patient group studied. 'Mixed adults' means 
the study included patients with spasticity of cerebral origin and patients with spasticity of 
spinal origin. 'Cerebral' means the study only included patients with spasticity of cerebral 
origin and 'spinal mainly adults'; means the study only included patients with spasticity of 
spinal origin, most of whom were adults. 
 
6.2.5 Outcomes Related to Mobility 
 
Because CIBI has an effect on the degree of spasticity, it can have an important effect on 
mobility. The proportion benefiting will clearly depend on patient selection, but the following 
figures are the best estimates available of the percentage of patients likely to benefit 
(rounded to the nearest 10%). 
 
 Around 70% of bed-bound patients may become able to sit out of bed in a chair.7,63,64,65 
 90% of wheelchair users who have difficulty sitting in a wheelchair, because of severe 
spasticity may become able to sit more comfortably
66,53,52
 and 70% of wheelchair users 
might improve their wheelchair mobility.
7,65
 Nearly all patients who can transfer report 
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improvements in ease of doing this.
66,56,53
  There have been a few reports of wheelchair-
bound patients who have become able to walk with aids, but this is a rare 
occurrence.
61,64,67
 
 The effect of CIBI on ambulation in those who can already walk to some extent has not 
been studied in many patients. The available evidence suggests that only around 30% of 
those who are already able to walk will improve their ability to do this and 10% may have 
a deterioration in walking ability.
56,62,65,67,68
 
 The extent of benefit is generally likely to be greatest in those with the most severe 
restrictions in mobility e.g. bed-bound patients and patients who find it difficult to sit in 
wheelchairs because of severe spasticity. 
 Most papers were not specific about the size of the improvements seen, so it is difficult 
to gauge how important these effects on mobility are.  
 
6.2.6 Effect on ADLs 
 
A number of papers report subjective improvements in ADLs.  
 Around 80% of patients may show some improvements in abilities to perform 
ADLs.
60,62,63
 The extent of improvement is generally not quantified, making it difficult to 
know how important the changes are. 
 Patients who are bed-bound with severe spasticity are unlikely to show any improvement 
in ADLs.
7,56,60,65,69
 
 
6.2.7 Effect on Dependency Levels and Nursing 
 
 One study has shown that some patients may improve their ability to live in community 
settings.
66
 
 In most patients ease of nursing care will improve, however no studies quantify the 
improvement in ease of nursing care.
6,7,53,66,52,69
 
 Patients who require help in dressing are likely to need less help, but it is unlikely they 
will become independent.
64
 Some patients who require help in feeding themselves may 
become independent in this.
64,70
  
 A number of studies have shown improvements in skin integrity.7,70,71 Chronic decubital 
ulcers may heal.
7
 This may be a very important outcome as ulcers may increase greatly 
the need for nursing care. 
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6.2.8 Other Outcomes which have an Impact on Quality of Life 
 
 Pain related to spasms is an important problem for some patients. CIBI appears to be 
effective in reducing or removing spasm-related pain. Approximately 90% of patients 
with spasm-related pain may benefit from a reduction in pain.
26,57,53,65,69,72
 Few studies 
had objective pain outcome measures or attempted to quantify the reduction in pain, so 
it is difficult to tell how important this may be.  
 Urinary function was reported to have improved in a number of studies. Improvements 
included decreased nocturia, becoming able to self-catheterise and becoming continent 
between catheters. Approximately 82% of patients with urinary problems showed some 
improvements.
58,61,67,68,70,72
 There are rare reports of patients being able to take up 
employment
55,73
 or go on holiday
74
 following CIBI. 
 Sexual functioning was reported to be improved in a very small minority of patients e.g. 
Ordia et al.
55
 reported improvements in four women out of 59 patients.  
 
6.2.9 Scoring Systems 
 
 A number of different scoring systems have been used to assess the effect of CIBI on 
function and quality of life, with differing results.
49,50,52,53,56
 
 The Sickness Impact Profile (the best validated of these scores) has been used in two 
studies.
49,50
 On long-term follow-up, both studies showed an improvement in physical 
dimensions of the score, however only one showed an improvement in psychosocial 
aspects of the score.
49
 The improvements seen were statistically significant, but of 
modest size. 
 Significant improvements have also been seen on the Functional Disability Score53 and 
the Functional Independence Measure.
56
 
 No significant changes have been observed in the Hopkins Symptoms Checklist,50 the 
Barthel score
52
 or the Ferrans and Powers Quality of Life Index.
49
 
 Some of the scores used may not be sensitive to change in these patient groups.  
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Table 4  Outcomes Related to Mobility 
 
BEDRIDDEN PATIENTS BECOMING ABLE TO SIT IN WHEELCHAIR 
Becker
7
 Cerebral adults 8/12 
Stewart-Wynne
63
 Mixed adults 6/6 
Ochs
64
 Mixed adults 22/38 
Zierski
65
 Mixed adults 14/20 
Overall 50/76 (66%) bedridden patients became able to sit in a chair.  
 
IMPROVED ABILITY TO SIT COMFORTABLY 
Becker
66
 6 MS patients On a 0-5 scale – average 3 point 
improvement in ability to sit  
Mertens
53
 Spinal adults 15/15 improved ability to sit comfortably 
Patterson
52
 Mixed adults 16/21 improved ability to sit comfortably 
Overall 31/36 (86%) had improved ability to sit comfortably. 
 
IMPROVED WHEELCHAIR MOBILITY 
Becker
7
 Cerebral adults 3/6  
Zierski
65
 Mixed adults 10/12 
Overall 13/18 (72%) improved wheelchair mobility. 
 
ABILITY TO TRANSFER IMPROVED 
Becker
66
 Mixed adults 8/9 major improvement 
Azouvi
56
 12 Adults with thoracic/lower 
cervical lesions 
Average improvement from 3.5 to 6.5 on 
a 1-7 scale. 
Mertens
53
 Spinal adults 17/17 improved ability to transfer 
Overall 25/26 (96%) had improved ability to transfer. 
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WHEELCHAIR BOUND PATIENTS BECOMING AMBULATORY (with aids) 
Concalves
61
 Cerebral adults 1/4 wheelchair bound developed 
'handicapped walking' 
Ochs
64
 Mixed adults 1/27 
Penn
67
 Mixed adults 2/5  
Overall 4/36 (11%) had developed 'handicapped walking'. 
 
AMBULATORY PATIENTS IMPROVING THEIR CAPACITY TO AMBULATE  
Broseta
68
 Mixed adults 1/7 
Azouvi
56
 Adults with lower cervical 
/thoracic lesions 
5/12 
(including 2/12 who became able to 
climb stairs) 
Zierski
65
 Mixed adults 3/5 
Penn
67
 Mixed adults 1 of 2 ambulatory patients lost ability to 
walk 
Gerszten
75
 Cerebral mean age 18 6/21 improved walking ability including 
4/7 who only walked in therapy became 
able to walk at home 
2/6 who only walked at home who 
became able to walk in the community 
(note 3 patients also had deterioration in 
walking ability) 
Overall 15/47 (32%) ambulatory patients improved their ability to walk and 4/47 (9%) had 
deterioration of their ability to walk. 
 
PATIENTS BECOMING ABLE TO DRIVE 
Parke
70
 Mixed adults 1/8 
Patterson
52
 Mixed adults 2/21 
Overall 3/29 (10%) became able to drive. 
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Table 5 Subjective Assessments of ADLs  
 
ACTIVITIES OF DAILY LIVING IMPROVED 
(subjective impression - no scoring systems used) 
Albright
60
 Cerebral mainly children 19/25 self caring patients 
0/7 non-self caring patients 
Gerszten
75
 Cerebral mainly children 20/24 (deteriorated in 2/24) 
Stewart-Wynne
63
 Mixed adults 6/6 
Overall 45/62 (73%) showed some improvement in ADLs. Improvements in ADLs were usually 
not seen in bed-bound patients. 
 
 
Table 6 Outcomes Related to Dependency Levels and Nursing 
 
PLACE OF RESIDENCE 
Becker
66
 Mixed adults Of the 3 patients who were hospitalised 
prior to CIBI, 2 became able to live in the 
community and 1 in a group home. Of 3 
patients in chronic care institutions prior 
to CIBI, 2 were able to move to a group 
home and one moved to hospital (due to 
comorbidities and progression of MS). 
 
NEED FOR PERSONAL ATTENDANT SERVICES 
Nance
8
 Mixed adults 2/7 had decreased need for personal 
attendants. 
 
ABILITY TO DRESS 
Ochs
64
 Mixed adults 8/12 patients who required major help in 
dressing required only a little help in 
dressing 6 months after CIBI. 
1/4 patients who required a little help 
became able to dress without help. 
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EATING ALONE 
Ochs
64
 Mixed adults 2/9 who required help became able to 
eat alone. 
Parke
70
 Mixed adults 5/7 who required help became able to 
eat alone. 
 
DEPENDENCY LEVEL 
Stewart-Wynne
63
 Mixed adults 6 adults – no measurable change in 
dependency levels. 
 
IMPROVED EASE OF NURSING CARE  
Albright
60
 Cerebral – mainly children 6/7 non-self caring patients. 
Becker
7
 Cerebral adults 18/18  
Becker
66
 Mixed adults 8/9 
Patterson
52
 Mixed adults 16/21 
Lazorthes
69
 Mixed – mainly adults 18/18 
Mertens
53
 Spinal adults 17/17 
Overall 83/90 (92%) had improved ease of nursing care. 
 
SKIN INTEGRITY 
Becker
7
 Cerebral adults Of 11 chronic decubital ulcers, 5 healed, 
5 improved. 
Becker
66
 Mixed adults 6/9 improved skin condition. 
Parke
70
 Mixed adults 3/3 with skin problems had resolution of 
problems. 
Overall 19/23 (83%) of patients with skin integrity problems showed improvements. 
 
 
 33 
 
Table 7  Other Outcomes Related to Quality of Life 
 
PAIN 
Broseta
68
 Mixed adults 9/10 with pain became pain free. 
Lazorthes
69
 Mixed 14/16 resolution of painful spasms. 
Loubser
57
 Spinal injury adults 6/6 with musculo-skeletal pain had 
complete resolution. 
6/6 with neurogenic pain had no 
resolution. 
Mertens
53
 Spinal - adults 9/9 with spasm related pain became pain 
free. 
Sahuquillo
72
 Mixed adults 8/8 with spasm related pain had relief. 
Zierski
65
 Mixed 13/17 with spasm related pain became 
pain free. 
Overall 59/66 (89%) of patients with spasm related pain had relief of complete resolution. 
 
SLEEPING 
Becker
66
 Mixed adults On a 0-5 scale sleep improved an 
average of 2.9 points, from 1.6 to 4.5. 
Penn
67
 Mixed adults 7/7 had improved sleep. 
 
SEXUAL FUNCTIONING 
Ordia
55
 Spinal adults 4/59 resumed sexual activity (all 
females). 
Loubser
74
 Spinal injury adults 1/7 improved sexual functioning. 
 
SOCIAL 
Patterson
52
 Mixed adults 2/21 improved social life. 
Penn
67
 Mixed adults 3/7 returned to work. 
Middel
50
  At 1 year no change on psychosocial 
dimensions of SIP score. 
Ordia
55
 Spinal adults 2/59 became employed. 
Loubser
74
 Spinal injury adults 3/7 became able to take vacations. 
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URINARY FUNCTION 
Broseta
68
 Mixed adults 5/9 bladder function improved. 
Parke
70
 Mixed adults 2/4 who were dependent became 
independent. 
Penn
73
 Mixed adults 4/4 who were incontinent between 
catheters became continent between 
catheters. 
Nanninga
58
 Spinal adults 4/4 who were incontinent between 
catheters became continent between 
catheters. 
3/3 patients with indwelling catheters 
became able to self catheterise. 
Concalves
61
 Cerebral adults 2/2 with bladder dysfunction showed 
improvement. 
Sahuquillo
72
 Mixed adults Of 3 with indwelling catheters, 2 had 
minimisation of leaks and 1 became able 
to self catheterise. 
4/4 with voluntary voiding had decreased 
nocturia. 
Overall 27/33 (82%) had improved urinary function. 
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Table 8 Studies Using Scoring Systems 
 
SCORING SYSTEMS 
Azouvi
56
 Spinal adults Functional improvement measure. 7 
point scale. Overall improvement in 
motor, but not cognitive domains. 
Minimum 2 point improvement in 
bathing, dressing lower body, transfers, 
and locomotion. 18 patients. 
Gianino
49
  Spinal adults Ferrans and powers Quality of life 
index – no improvements. 
Sickness Impact Profile (0-100 scale) 
improved from 29.7 to 21.7. Physical 
sub-score improved from 38.5 to 31.0. 
Psychological sub-score improved from 
20.8 to 13.0. Changes were measured at 
12 months in 16 patients and were 
statistically significant (p<0.005). 
Mertens
53
 Spinal Adults Functional Disability Score - 
composite score measuring pain, 
spasms, wheelchair use, transfers and 
washing/dressing each on a 4 point 
scale decreased from 13.4 to 5.8 
(p<0.0001). (17 patients). 
Middel
50
 Spinal adults Hopkins Symptom Checklist and 
Sickness Impact Profile - no difference 
between placebo and intervention group 
at 3 months. 
At 12 months physical sub-score of 
sickness impact profile improved from 
41.5 to 31.5. No change on psychosocial 
sub-score. 
Patterson
52
 Mixed adults 0/21 showed improvements in Barthel 
score. 
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6.2.10 Complications Associated with CIBI 
 
The studies included in the review were also examined to extract data on side-effects. 
Studies that systematically reported side-effects and in which the type of pump used was 
know, were summarised in Table 9. 
 
Table 9 Complications Associated with CIBI 
 
 Type of Pump 
Complication Medtronic (222) Cordis Secor (30) Infusaid (43) 
Death due to 
pulmonary embolus  
(Unknown if related to 
pump) 
 2 (0.9%) 0  1 (2.3%) 
Deep vein thrombosis 0  2 (7%) 0 
Meningitis  1 (<1%)  6 (20%)  2 (5%) 
Overdose  5 (2%)  4 (13%)  2 (5%) 
Pump removal due to 
complication 
 16 (7%)  9 (30%)  1 (2%) 
Catheter problems 
requiring surgery 
 37 (17%) 0  7 (16%) 
Local infection  9 (4%)  7 (23%) 0 
Constipation  13 (6%)   
Erectile Dysfunction  7 (3%)   
Urinary retention  6 (3%)   
CSF leaks  5 (2%)   
Skin erosions over 
pump 
 3 (1%)   1(2%) 
Pseudomeningocoele  1 (<1%)   
Epileptic seizure  1 (<1%)   
Pocket seroma  1 (<1%)   
 
Deep vein thrombosis and pulmonary embolism are likely to occur more frequently in this 
patient group because of poor mobility. Therefore, it is unlikely that the reported incidents of 
 37 
 
these conditions were directly related to use of the pump. Serious complications such as 
meningitis or overdose appear to be rare when the Medtronic pump is used. Up to 7% of 
pumps may be removed because of complications. Problems with the catheter, e.g. 
blockage or kinking requiring minor surgical intervention, are the most common problems 
with the procedure. 
 
6.2.11 Summary of Effectiveness of CIBI 
 
Continuous intrathecal baclofen infusion has been shown to produce a major reduction in 
severe spasticity of spinal origin in most patients. The effect on spasticity in patients with 
severe spasticity of cerebral origin is likely to be less, but useful changes are also seen in 
this group. 
 
The quality of the evidence to demonstrate the effectiveness of CIBI is generally poor 
(consisting almost entirely of small, open, uncontrolled follow-up studies with subjective 
outcome measures and a failure to report results separately in different patient groups). 
However, the quantity of the evidence is now quite large and many studies show important 
effects in some patients. 
 
Decisions about whether or not to use CIBI need to be based on an understanding of the 
likely benefits in patients with different levels of function: 
 
 Patients with very severe spasticity who are bed-bound and difficult to nurse are likely to 
benefit from being able to sit out of bed. Nursing care is also likely to be easier. Such 
patients are very unlikely to have improvements in ADL.  
 
 Patients who use wheelchairs but have great difficulty in being seated in the chair are 
likely to benefit by being able to sit much more comfortably. 
 
 Patients with a reasonable degree of remaining function may show some improvements 
in their ability to perform important functions such as transfers, feeding, dressing or 
wheelchair mobility. Most studies do not quantify the level of improvement, so it is 
difficult to judge from the literature how great that improvement may be. Failure to show 
large improvements in functional measures, such as the Sickness Impact Profile, 
suggest that such improvements may be modest. It is very unlikely that patients will 
show dramatic improvements in function, although there are a few reports where this 
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has occurred. The vast majority of patients will still need help to perform many of their 
activities. However, in severe disability even modest improvements in function may be 
very important to patients.  
 
The evidence for using CIBI to improve walking ability is very limited. Up to one third of 
ambulatory patients may show some improvements in ambulation, but these improvements 
are unlikely to be dramatic. Some patients may find that the loss of tone makes walking 
more difficult. 
 
Significant pain related to spasms and problems with skin integrity strengthen the case for 
using CIBI. CIBI may also improve urinary function, but patients are still likely to need to 
self-catheterise. 
 
The benefits need to be weighed against the risk of complications (major complications 
appear to be rare when the Medtronic pump is used), the inconvenience of needing 
regularly to have the pump refilled, and the cost of the procedure.  
 
6.3 ECONOMIC ANALYSIS 
 
6.3.1 Estimation of Net Benefits 
 
Estimation of the benefits of CIBI is not straightforward as there is no standard outcome 
measure used to quantify the benefits. CIBI does not aim to provide a ‘cure’ for spasticity, 
but aims to manage the condition in terms of easing pain, ability to transfer and patients' 
quality of life. Although the Ashworth scale is the most commonly reported scale, this is not 
considered meaningful in terms of reflecting a patient’s quality of life. None of the studies 
identified reported standard quality of life (QoL) measures for patients using CIBI, although 
a number reported improvements in patients' quality of life. As such, it has not been possible 
to estimate the benefits in terms of quality adjusted life year (QALY)s gained. Potential cost-
utility results are discussed later, using threshold analysis to examine the QoL benefits 
required to produce a cost-utility estimate within acceptable limits. 
 
6.3.2 Estimation of Net Costs   
 
Intrathecal baclofen is considered only for patients with spasticity that have not responded 
sufficiently to any other forms of treatment or in whom side-effects of oral treatments were 
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considered unacceptable. These patients are functionally dependent and require almost 
constant care. Patients with severe spasticity use a variety of health and social service 
resources, receiving care at home and within hospital or care home setting.  
 
The use of CIBI has been shown to reduce spasticity and improve the functional outcomes 
for patients, increasing their independence, comfort and facilitating the job of the carer. 
Despite a high cost of initiating therapy, the costs may be offset by reductions in future costs 
for the management of spasticity. There may be potential for cost savings in other areas, 
such as a reduction in bed days used for the management of spasticity and reductions in the 
number of orthopaedic procedures required. 
 
It is difficult to quantify benefits for CIBI in terms of improvements to the quality of life of 
both the patient and the carer. Therefore, the authors have not considered the cost-utility of 
CIBI, but compared the cost of CIBI with the healthcare costs of alternative interventions. No 
formal economic analysis of CIBI incorporating consideration of benefits has been identified 
from the existing literature, although a number of cost analyses are identified and discussed. 
 
6.3.3 NHS Costs of Intrathecal Baclofen 
 
The costs of intrathecal baclofen arise from the cost of the procedure, costs of follow-up, 
support and costs of potential complications. The initial high cost of CIBI therapy arises from 
screening, the cost of the pump and the hospitalisation required to establish dose 
requirements. Following the initial hospitalisation, the costs are reduced considerably. The 
pumps will require a refill every two to three months, and this will normally take place on an 
out-patient basis. 
  
The cost of hospitalisation reported within the literature varies depending upon whether 
complications are experienced. The cost studies identified include substantial costs 
associated with the management of side-effects. However, costs of complications should be 
less significant than those reported in many of the studies due to improvements of the pump 
itself and the experience of the surgeons.  
 
The typical length of stay in an acute care facility after an uncomplicated implant has been 
reported to be between 3 and 10 days.
76,77,78 
The average length of stay within an in-patient 
ward for the UK is considered to be around five days. 
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Screening costs will be incurred for all patients who may be considered suitable for CIBI 
therapy, including those who do not respond to the bolus dose. The test dose CIBI is given 
before the pump is implanted to establish the patient’s responsiveness to the drug. The test 
dose is either by means of lumbar puncture or using an indwelling catheter. This requires 
hospitalisation of around two to three days, with patients usually observed on a general 
ward, but with access to intensive care, if required (due to the potential of an anaphylactic 
response). Around 70%-80% of children tested for response to intrathecal baclofen will 
undergo implantation.
79
 
 
The batteries in the CIBI pumps have a limited lifetime after which the pump must be 
replaced. In the older pumps battery life is approximately 4-5 years and in the most recent 
pumps the battery life is seven years (SynchroMed Infusion System, Medtronic). Replacing 
the pump involves a procedure similar to the initial implant. However, optimally, the pump is 
removed without affecting the catheter, in which case the procedure is less lengthy and 
requires less time in hospital. The procedure may be associated with an increased risk of 
infection, as is the initial pump implantation. 
 
Further costs will be incurred due to training requirements for carers, hospital staff and 
specialised nurses. There will also be further educational requirements for the GP, patient 
and family. This is an ongoing process consisting of an initial introduction to CIBI therapy, 
further information once therapy has been chosen, and then advice on the follow-up 
procedure and the degree of commitment required. Information will need to be provided on 
the delivery system, frequency of pump refills, methods to assess improvements and 
potential complications, such as, adverse skin reactions, overdose and so on. Intensive in-
patient rehabilitation for some patients is also necessary so that the patient can learn new 
living techniques in order to maximise the benefit of CIBI.  
 
The question as to whether the need for physiotherapy increases or decreases following 
CIBI is debated.
41,75
 Albright
80
 suggests that the frequency of physical therapy after pump 
insertion depends on the goal of the treatment; if the goal is to improve gait, therapy is often 
given three times a week. If the aim is to facilitate care, patients may need therapy once a 
week to maintain range of motion, or not at all. 
 
The costs associated with CIBI have been estimated using costs from the Queen's Medical 
Centre (Nottingham) and the Leicester Royal Infirmary. The cost of administering the test 
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dose, pump implantation and equipment is estimated at between £10,500 and £12,900. 
Additional annual costs of around £580 to £870 were estimated for follow-up and refill.  
 
The costs are broken down as follows: 
 
 Pre-screening costs (including 30 minutes neurosurgeon time and 
out-patient clinic visit)  
 
 £330 - £556 
 Test dose (including lumbar puncture, lumbar catheter, procedure 
(HRG A452 – injection of therapeutic substance), 2 days' 
hospitalisation, drug costs and physiotherapist and nursing time for 
patient observation)  
 
 £940 - £1,570 
 Cost of pump and catheter  
 
  £7,000  
 Cost of implantation procedure (including cost of procedure, drugs, 
5 day in-patient stay   
 
  £8,730 - £10,260 
 Other costs (tests, pathology, radiology, microbiology, excluding 
potential transport costs)  
 
 £550 
 Cost of follow-up (including refill kit, drug costs, physiotherapist 
assessment and out-patient visit)  
 
 £140 - £150 
Further details of the cost breakdown are provided in Appendix E. 
 
These assume no costs related to complications. The Paediatric Intensive Care Unit (PICU) 
may be needed when CIBI is administered to children with CP, due to potential anaphylactic 
response. The cost of the PICU at the Queen's Medical Centre is currently £1,500 per day 
and, thus, will, increase costs considerably. However, the potential for incurring these costs 
is difficult to estimate and has not been reported within any published UK study.  
 
The majority of complications will occur within the first few months following implantation, 
with further complications potentially arising from inappropriate dosage. The potential for 
error depends upon the experience of the surgeon, cognitive function of patients (related to 
patient selection) and carers. 
 
6.3.4 NHS Savings from Use of New Intervention 
 
Following CIBI therapy, patients experience a decrease in spasticity which can lead to 
improved mobility and ease of care, and consequently they require fewer resources for 
management of the spasticity. The reduction in spasticity may lead to fewer carers being 
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needed for an individual patient and reductions in the requirement for institutional care, 
orthopaedic surgery, orthoses and other supporting aids. Reductions in the number of bed 
days required for the management of spasticity have been reported, notably due to the 
decreased likelihood of developing pressure sores following reductions in spasticity. In 
addition, savings may be realised from the reduced need for oral drugs or other 
interventions to treat spasticity. 
 
The potential savings are not well quantified in the literature, although there are a number of 
articles which examine the potential savings resulting from reductions in bed days and one 
which reports upon the reduced need for orthopaedic surgery. There are no UK studies of 
costs or savings relating to the use of CIBI.  
 
a) Reductions in Hospital Stay 
 
Patients with severe spasticity frequently require hospitalisation for the treatment of 
problems related to the spasticity. Patients often require hospital stays of several months for 
the management of bedsores due to long-term immobility resulting from the spasticity. Other 
patients will require hospitalisation for periods when the spasticity is so severe that the 
burden of care is too much for them to be looked after within the community. 
 
The impact on hospitalisation requirements following CIBI have been reported for the US,
55
 
Canada
8,66
 and the Netherlands.
81
 The conclusions of these studies are detailed in Appendix 
F. 
 
The savings reported by Nance et al.
8
 and Becker et al.
66
 refer only to hospitalisation days 
related to spasticity. Nance reports a 40 day average reduction in the number of bed days 
used over two years and Becker reports a 55 day average reduction in the number of bed 
days used over one year. The difference in numbers could be due to a greater degree of 
disability in the population reported by Becker, as there were patients suffering skin 
breakdown who had considerable resource requirements. 
 
The savings reported by Ordia et al.
55
 do not relate specifically to spasticity and there is no 
information provided as to the reason for hospitalisation prior to or post CIBI. Further 
information would be required in order to consider the use of the results of this analysis. 
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Postma et al.
81
 provide a detailed cost analysis of the costs and savings of CIBI in the 
Netherlands. The study showed no significant difference in the number of hospital days 
used by patients undergoing CIBI and the control group in the year following CIBI. For the 
implantation year there were 18.7 days used on average by the control group compared to 
an estimated average of 20.7 days related to the CIBI procedure and no further days related 
to spasticity for the CIBI group.  
 
These papers provide three estimates of bed days used for patients without or prior to CIBI; 
19 days,
37
 32 days (63 days over 2 years)
8
 and 84 days.
66
 The differences are due to 
different patient selection and care settings. Assuming an average cost per in-patient day of 
£211,
82
 this represents costs of £4,000, £6,800 and £17,700 respectively. 
 
The number of bed days used during the year of implantation ranges from 21 days
81
 to 29 
days.
66
 This corresponds to costs of £4,400 to £6,100 for the hospitalisation related to the 
CIBI procedure. 
 
b) Pressure Sores / Decubitus Ulcers 
 
Pressure sores are a considerable risk for patients who are bed bound due to spasticity. The 
cost of treating pressure sores is substantial, as they require either long periods of 
hospitalisation or intensive community nursing care. It is estimated that the total national 
cost in the UK for the treatment of pressure sores is approximately £755 million a year.
83
 For 
example, a full thickened sacral ulcer extends hospital stay by over 25 weeks at a cost of 
£26,000 including extra staffing, drugs, dressings and hospital overheads.
83
 Costs for 
pressure ulcers differ depending on the ulcer stage, and also vary depending on care 
setting. One US study found the mean costs varied from US$1.55 per day for a stage 1 
ulcer to US$6.03 per day for a stage 4 ulcer in 1992.
84
 Local estimates of costs for treating 
pressure sores are around £17,000 for a grade 4 pressure sore and £5,000 for grade 3/4.
85
 
Research is lacking in many areas of pressure ulcer prevention and treatments with regards 
to cost-effectiveness.  
 
c) Orthopaedic Surgery 
 
The use of CIBI in patients with spasticity due to CP may defer the onset of muscle 
contractures, hip dislocations and potentially reduce the onset of scoliosis.
86
 The resulting 
reduction in the need for orthopaedic surgery for patients undergoing CIBI has been 
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reported.
75 
This paper suggests a reduction of 66% in orthopaedic operations needed 
following CIBI. While it is not clear whether these procedures have been avoided or merely 
delayed, there is clearly potential for cost savings.  
 
Neither the actual operations avoided, nor the costs associated with these procedures is 
documented within the article. Local costings
86
 report the costs of common orthopaedic 
procedures for this patient group as follows: 
 
Adductor releases  £2,000 
Open or closed adductor tenotomy  £1,500 - £2,000  
(excl. physiotherapy) 
Hamstring release  £2,500  
Salter’s osteotomy or Chiari osteotomy (for hip dislocation)  £5,000 
 
The number of orthopaedic procedures avoided depends upon the age of the child. When 
the child is treated within the early stages, it is considered likely that orthopaedic procedures 
may be avoided altogether. In the older child (7-10 years) further orthopaedic work, e.g. 
Achilles tendons and hamstring releases, may be necessary. 
 
d) Reductions in Oral Treatments or Other Interventions 
 
The cost of the drug for CIBI should be offset by reductions in oral treatments, which are 
prescribed in considerably higher doses. The use of CIBI may also reduce the need for 
interventions such as therapeutic nerve blocks.  
 
e) Orthoses and Other Aids or Adaptations 
 
Patients with severe spasticity require considerable resources. Improved management of 
spasticity may lead to a reduction in seating aids, wheelchairs, spinal jackets (due to 
scoliosis) and orthoses.
86
 Reductions in spasticity have also been reported to decrease the 
need for specially designed wheelchairs designed to accommodate extended legs due to 
spasticity and allow patients to switch to less expensive compact models.
76,78
 The compact 
wheelchair means there is no need for remodelling of the home hallway and fewer 
adaptations are required. 
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There are currently no data available to quantify these potential savings, although 
anecodotal evidence suggests the savings will be realised. Examples of potential cost 
savings from the reduced need for home adaptions are as follows: 
 
Redesign bathroom:  £1,925 (median)
82
 
Redesign kitchen:   £2,282 (median).
82
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f) Reductions in Care Resources 
 
One area of potentially significant savings following CIBI, which is not well documented 
within the literature, is the potential reduction in carers' time and the need for nursing home 
care following a reduction in spasticity. Due to the intensity of care required for patients with 
severe spasticity, any reductions in care requirements will represent considerable cost 
savings. 
 
The use of CIBI to manage spasticity may reduce carers' time significantly as improved 
sleep may lead to reductions in night care and patients will be able to be seated and 
dressed more easily, sometimes reducing the number of carers required to assist one 
person. Although reductions in the caregiving time required and the ease of care are 
frequently reported
8,66,76,87
 there is no quantification of the potential savings which may be 
realised. 
 
Similarly, savings have been reported in terms of reductions in the need for institutional 
care,
66,81
 but the potential scale of the cost reduction is not quantified. 
 
g) Indirect costs 
 
Further potential impact on costs may be achieved through indirect costs, as some patients 
have been reported to return to employment following CIBI
8,81
 or been able to further their 
education due to reductions in spasticity. Again, these costs are not quantified within the 
literature.  
 
6.3.5 Estimation of Cost-effectiveness and/or Cost-utility 
 
The central cost estimate of CIBI is estimated at around £11,700 per patient for the 
screening and initial implantation, including £6,770 for the cost of the pump. This is based 
upon a hospital stay of two days for the test dose and five days for the implantation phase. 
Costs were obtained from the Queen's Medical Centre (Nottingham), Leicester Royal 
Infirmary and Central Sheffield University Hospitals NHS Trusts, using an average of the in-
patient costs per day. Costs per day varied depending upon the type of ward used (i.e. 
paediatric neurosurgery or neurology ward). The cost of refills and follow-ups are estimated 
at around £867 per annum, again using an average of costs from the three Trusts and 
assuming six refills per year. This gives a total cost of around £15,900 for a five year period 
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and £17,600 for a seven year period, depending upon the type of pump used. The number 
of years of benefit received depends upon the type of pump used and the condition of the 
patient. Some severely disabled MS patients may have a reduced life expectancy when 
undergoing implantation for CIBI.    
 
Gross costs were used as there is no evidence available quantifying the potential savings. 
Also, the potential to achieve savings and to shift resources is not always realisable.  
 
Discounting costs at a rate of 6%, gives a total current value of £15,400 for a five year 
period and £16,700 for a seven year period.  
 
As there is no quantified measure by which the QALYs gained by the use of CIBI can be 
measured, it is not possible to provide an estimate of the cost per QALY for the treatment. 
However, by performing threshold sensitivity analyses, an indication of the potential cost-
effectiveness can be provided.  
 
Scenario 1:  Using Average Costs per Year Over the Period of Treatment 
 
Assuming total costs of £17,600 for seven years' treatment, i.e. an average cost per year of 
£2,500, a benefit of 0.13 QALYs per year (i.e. 0.88 QALYs for the seven year period) would 
produce a cost-effectiveness ratio of £20,000. 
 
Assuming total costs of £15,800 for five years' treatment, i.e. an average cost per year of 
£3,200, a benefit of 0.16 QALYs per year (i.e. 0.79 QALYs for the seven year period) would 
produce a cost-effectiveness ratio of £20,000. 
 
Scenario 2:  Discounting Costs and Benefits to Account for Different Costs in Each Year 
 
Assuming a cost of £11,870 in year one and £870 in following years, and discounting both 
costs and benefits at 6%, the number of QALYs gained over the seven year period would be 
0.83 to produce a cost-effectiveness ratio of £20,000, i.e. 0.14 QALYs for year one. 
Assuming the pump lasts for five years, and discounting costs and benefits at 6%, the 
number of QALYs gained over the period would have to be 0.77 to produce a cost-
effectiveness ratio of £20,000, i.e. 0.17 QALYs in year one. 
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6.3.6  Sensitivity Analyses 
 
This section will examine the impact of altering assumptions surrounding different 
parameters upon the cost estimates and results of the cost-effectiveness analyses. 
 
a) Ranges in Costs 
 
The costs used for CIBI may vary between centres and costs will vary depending upon the 
care setting, with paediatric neurosurgery wards being generally more expensive than 
neurology wards. The cost of the intervention is dependent upon assumptions made relating 
to the number of in-patient days required for the test dose, the implantation procedure, the 
management of potential complications and the number of follow-up visits required. 
Discussion with clinicians suggested that the range of days for the test dose was 2-5, with 
the mean in-patient stay for implantation procedure of between five and seven days. The 
number of refills per year ranged from four to 10, with an average of six. Extreme sensitivity 
analyses using our ranges of costs and parameter estimates suggest the cost of 
implantation of a CIBI pump could range between £10,500 and £15,700. These estimates 
are based upon the range of days listed above, using cost per day of £245 - £551 and do 
not include the cost of follow-up or refills. The cost of follow-up is estimated to range from 
£578 to £1,400 per annum, using a range of 4-10 visits per annum. 
 
There may be a small risk of PICU requirement for patients with CP and occasional 
complications may require additional resources, although clinical opinion suggests that 
complications are rare, with the exception of catheter related problems which can be fixed 
easily and do not require extensive hospitalisation. Postma et al.
81
 reported a mean 
additional length of stay of 8.4 days for the management of complications related to the 
procedure.  The necessity for PICU is not quantified within the literature and has not been 
quantified by clinical opinion. 
 
b) Sensitivity of Cost per QALY Assumption to QALY Gains and Treatment Costs 
 
In order to demonstrate the relationship between variance in cost, cost-utility ratio and QALY 
gains, the following graph (Figure 1) tracks the annual gains in health state values (QALY 
gains) required to provide cost-effectiveness ratios of between £5,000 and £25,000 per 
QALY. The following tables and graphs assume that five years of benefit are derived. 
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Table 10 presents the number of QALYs that the treatment would need to provide per 
annum to achieve different levels of cost-effectiveness, based upon variance in the initial 
cost of the treatment and discounting costs and benefits at 6% per annum. As the cost of 
the pump and the in-patient stay for implantation are the largest cost elements, variance in 
the initial cost will have the greatest effect upon cost-effectiveness. The impact of altering 
the cost of refill/follow-up depending upon the number of refills per year is significantly 
lower. 
 
Table 10 Annual Gains in Health State Values (QALY Gains) Required per Year of 
Treatment for Different Cost-Utility Ratios and Initial Treatment Costs. 
Costs and Benefits Discounted at 6% per Year Over a 5 Year Period. 
 
5 Year Scenario Only
DISCOUNTED Initial Cost of Treatment
Cost per QALY ratio £10,000 £12,000 £14,000 £16,000
£5,000 0.58        0.67        0.76        0.85        
£10,000 0.29        0.34        0.38        0.43        
£15,000 0.19        0.22        0.25        0.28        
£20,000 0.15        0.17        0.19        0.21        
£25,000 0.12        0.13        0.15        0.17         
 
 
Figure 1 Sensitivity of Annual QALY Gains to Initial Treatment Cost and Cost per 
QALY Assumptions 
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This graph suggests that a likely QALY gain of between 0.10 and 0.20 per annum would be 
expected to provide a cost-utility of around £20,000 per QALY. Clinical opinion (meeting of 
the Trent Working Group on Acute Purchasing) suggested that this scale of improvement in 
QoL would be achievable. 
 
 
c) Example of Equivalent Health States Providing QoL Utilities of 0.1 – 
0.2 
 
There are no quality of life studies reported for CIBI and, thus, it is not possible to estimate 
the cost per QALY using conventional cost-utility analysis. In order to indicate the potential 
changes in health state which would provide a change in health state utility of between 0.1 
and 0.2 QALYs, the authors referred to the Index of Health Related Quality of Life measure 
(IHQL) to estimate potential QoL indices for patients utilising CIBI. The classification of 
these health states are provided in Appendix G.  If it is assumed that a patient pre-CIBI is 
confined to bed (state D7), has severe pain (state P3) and is moderately distressed (anxious 
and depressed most of the time, but happy and relaxed some of the time) (state E3), the 
patient will be associated with a utility of 0.449. If post-CIBI the patient has the same 
distress and disability, but a reduction in pain to slight pain, then he/she will be associated 
with a utility score of 0.675. The QALY utility gain will be 0.226. If the pain were reduced 
only to moderate pain, the QALY utility gain would reduce to 0.149. If CIBI resulted in an 
improvement in pain to moderate pain levels and the patient also experienced a reduction in 
disability to state D6 (confined to a chair, only able to get out with assistance, very limited 
ability to perform role functions), he/she would experience a QALY utility gain of 0.199. 
 
These examples are not based upon real-life experience of benefits from CIBI, but are 
indicative of the relevant QALY utilities gained from reductions in pain and disability. 
Similarly, the IHQL was used as an indicative QoL utility score and may not be the most 
relevant QoL indicator for this evaluation.  
 
d) Consideration of Potential Savings  
 
The potential savings due to reduced resource requirements for the management of 
spasticity are detailed below. 
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i) Hospitalisation 
 
Reductions in the need for hospitalisation were reported within the literature. These studies 
considered patients with SCI, head injury or MS. The reduction in bed days has been 
reported as between 20 days
8
 and 55 days
66
 per year.  
 
This equates to savings of between £11,020 and £30,300 per annum, based upon costs of 
£551 per day (Queen's Medical Centre). This may be an over-estimate as this cost per day 
is based upon stay on a paediatric neurosurgery ward.  Assuming average in-patient costs 
per day of £211,
82
 this would equate to savings of between £4,220 and £11,600 per annum. 
 
Assuming the lower cost estimate, costs could be saved for each year of therapy; savings 
could range from £21,000 to £58,000 for five years of therapy (£18,800 to £51,800 
discounted at 6% per year). 
  
ii) Pressure Sores 
 
The reduction in bed days may be due partially to the reduced need for the management of 
pressure sores. None of the cost studies related to CIBI examined the cost consequences 
or nursing requirements related to a reduction in pressure sores, although the cost 
consequences of pressure sores have been reported elsewhere.
83,84,85
 The cost of treating a 
grade 4 pressure sore has been reported at between £17,000 and £26,000. Assuming 
patients with MS or SCI have a 50% chance of developing a grade 4 pressure sore over the 
five year period, this could result in an average saving of £8,500 - £13,000 per patient. 
 
iii) Orthopaedic Surgery 
 
The costs of orthopaedic surgical procedures have been estimated at between £1,500 and 
£5,000 depending upon the operation required. Assuming all patients with CP will avoid at 
least one orthopaedic procedure within five years of implantation, orthopaedic surgery costs 
of between £1,500 and £5,000 may be avoided. These figures may be an under-estimate as 
patients frequently undergo multiple orthopaedic procedures. 
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Table 11  Summary Table of Potential Savings 
 
Reductions in hospitalisation 
(MS & SCI) 
Avoidance of 20 days' 
hospitalisation 
 £4,220 
 Avoidance of 55 days' 
hospitalisation 
 £11,605 
   
Orthopaedic surgery (CP) Avoidance of 1 adductor 
release 
 £2,000 
 
Avoidance of 1 open or 
closed tenotomy 
 £1,500 
 
Avoidance of 1 hamstring 
release  
 £2,500 
 
Avoidance of hip dislocation  £5,000 
   
Pressure sore (MS & SCI) 50% chance of avoiding 
pressure sore – using cost of 
pressure sore of £26,000
83
 
 £13,000 
 
50% chance of avoiding 
pressure sore – using cost of 
pressure sore of £17,000
85
  
 £8,500 
*Savings per year based upon cost per in-patient day of £211
82 
 
6.3.7  Summary of Economic Analysis 
 
The cost of CIBI is estimated at around £11,700 for the initial assessment, test procedure, 
implantation procedure and equipment. In addition, there will be further costs of around 
£870 per annum for refill and follow-up. The treatment may last for up to seven years, 
depending upon the type of pump used, although life expectancy may be less than this 
period for some patients, notably MS patients. There are no studies reporting upon QoL 
utilities for CIBI. Assuming five years of benefit are obtained from the pump implantation, an 
average annual QoL utility gain of around 0.16 would result in a cost-utility ratio of £20,000. 
Clinical opinion and IHQL analysis suggested this scale of QoL improvement to be possible.  
 
Moreover, the high initial cost of CIBI implantation could be offset substantially by reductions 
in pressure sores, other admissions related to spasticity, orthopaedic procedures and 
reductions in requirements for orthoses or other aids and adaptations. 
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7. OPTIONS FOR PURCHASERS/COMMISSIONERS  
 
Due to problems with the methodology of most trials of CIBI, it is not possible to make a 
definitive statement about the recommended option for purchasers. Whilst it is likely that 
CIBI would be of benefit to selected groups of patients, especially those most disabled by 
their spasticity, very little is known about the cost-effectiveness of the intervention.   
 
Option 1   Do nothing and await further evidence 
  
Rigorous, large, multi-centre randomised controlled trial/s with long-term follow-up, 
appropriate outcome measures and good quality information on costs would be required to 
progress the current state of knowledge.  
 
Option 2   Provide CIBI only in the context of high quality trials 
 
A nationwide multi-centre controlled trial, ideally randomised, could provide better evidence 
of the effectiveness and cost-effectiveness of this procedure and the groups who might 
benefit.  However, the study would need to have a long follow-up period, use appropriate 
functional outcome measures and be sufficiently large to allow estimation of the effects in 
different pathological and disease-severity groups. It might not be considered ethical to 
withhold CIBI from groups where there is already some evidence of benefit. 
 
Option 3  Provide CIBI only in those patient groups in which there is most 
evidence of benefit.  Provide CIBI in other patient groups only in the 
context of high quality trials 
  
Groups for which there is reasonable evidence of likely benefit include:- 
 
 Patients who are bedbound due to severe spasticity; 
 Patients who cannot be seated appropriately in a wheelchair due to severe extensor 
spasms;   
 Other wheelchair bound patients in whom spasm related pain or skin breakdown is a 
severe problem. 
 
 54 
 
It would be valuable to set up a nationwide multi-centre scheme to collect further information 
on outcomes in these patients. It is recommended that all children receiving CIBI should be 
part of a well co-ordinated national research study. 
 
Groups for which the evidence of benefit is less clear include:-  
 
 Wheelchair users who already have a reasonable degree of function;* 
 Ambulatory patients. 
(* excepting patients experiencing severe frequent spasm related pain or skin breakdown 
which cannot be managed with other interventions.) 
 
The evidence is insufficient to justify routine use in these patients.  Thus, CIBI should only 
be provided in the context of a high quality RCT with long-term follow up using appropriate 
functional outcome measures. 
 
Option 4  Provide intrathecal baclofen for all patients with severe spasticity whom 
clinicians judge to be likely to benefit, but ensure that good quality data 
are collected on outcomes. 
 
This is unlikely to advance significantly the state of knowledge on this procedure, and could 
lead to some patients in whom there is minimal evidence of effectiveness receiving 
treatment.   
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8. DISCUSSION AND CONCLUSIONS  
 
Many studies describe the benefits of CIBI in patients with spinal and cerebral spasticity. 
However, most of these studies fail to report functional outcome measures and concentrate 
on less clinically meaningful measures such as the Ashworth scale.  Almost all studies are 
open follow-up studies with no control groups. The one reported randomised controlled trial 
of CIBI  demonstrated no significant difference between the treatment and placebo group in 
functional or QoL outcomes at three months.  However, it is possible that the measures 
used were not sufficiently sensitive to detect clinically important differences. 
 
Despite the methodological drawbacks, the range of benefits and the proportion of patients 
benefiting was reasonably consistent across studies. In particular, it was reported 
consistently that bed-bound patients often became able to sit out of bed, wheelchair users 
who were unable to sit comfortably because of spasticity were able to sit more comfortably, 
spasm related pain was decreased and ease of nursing care was increased.   
 
Patients who are likely to obtain the most benefit from CIBI are those who are bed-bound or 
are unable to sit comfortably in a wheelchair due to severe spasticity.  In patients who are 
wheelchair-bound, but have a reasonable degree of functional ability, the benefits are likely 
to be less marked, although those with severe spasm related pain or problems with skin 
integrity may benefit more.  There has been insufficient research on the effects of CIBI in 
ambulatory patients.  The available research suggests that only a minority of such patients 
will benefit and some will deteriorate. 
 
The estimate of cost-effectiveness of CIBI is difficult due to the lack of trials examining QoL 
measures. The treatment is estimated to cost around £15,000 and will provide benefit for 
around 5-7 years. Savings may be incurred due to reductions in hospitalisations related to 
spasticity, pressure sores and orthopaedic procedures. Threshold analysis suggests that the 
cost-utility is likely to be in the same range as coronary artery bypass surgery, peritoneal 
dialysis or home haemodialysis, even for gross cost-utility, excluding potential savings. 
 
The use of CIBI should be considered only after patients have undergone a full assessment 
to ensure any potential underlying aggravating factors have been eliminated and all other 
potential avenues for treatment have been explored. Patients should be given realistic 
descriptions of the benefits which are likely to be achieved and the possible adverse effects.  
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CIBI should be initiated by specialist teams which are able to assess the suitability of the 
patient, fit the pump and arrange regular follow-up.  
If such a service is to be commissioned, it should work to clear guidelines detailing which 
patients are suitable for treatment and which patients should only be treated in the context 
of high quality research studies. 
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APPENDIX A   STUDIES INCLUDING PATIENTS WITH SPASTICITY OF SPINAL ORIGIN 
 
Trial, 
Year, 
Review 
Number 
Inclusion (I) 
Exclusion (E) 
Description of 
Patients 
Intervention 
and Duration 
of Follow-Up 
(Mean-Range) 
Results (subjective measures used unless otherwise   
stated) 
Comments 
Azouvi 
1996
56
 
I - Severe and 
disabling 
spasticity, 
ineffectiveness 
of oral drugs, 
positive 
response to 
bolus. 
E - infectious 
problems, 
bedsores, 
psychiatric 
disorders. 
18 patients  
 
12 SCI,  
4 MS,  
1 
Syringomyelia,  
1 tropical 
paraplegia. 
 
All non-
ambulatory 
 
Mean age 38 
(21-59) 
37.4 months 
(9-72) 
17 
programmable 
1 mechanical 
Functional Improvement Measure (composite score 
measuring different functions on a 7 point scale).  
Overall score improved for motor domains of score, but 
not cognitive domains. 
 
Most dramatic improvements were in 12 patients with 
thoracic or lower cervical lesions.  (At  least 2 point 
improvement in bathing, dressing lower body, transfers 
and locomotion aspects of FIM. 
2/12 became able to sit in chair, 5/12 walking ability 
improved, including 2 who became able to climb stairs)  
 
Improvements in the 6 most severely disabled patients 
was confined to improvements in sitting position and 
ease of nursing care. 
Patients with 
useful upper 
limb function 
likely to show 
measurable 
improvements 
in ADLs. 
Patients 
without upper 
limb function 
are unlikely to 
show 
improved 
function, but 
may benefit 
from improved 
sitting position 
and ease of 
nursing care. 
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Trial, 
Year, 
Review 
Number 
Inclusion (I) 
Exclusion (E) 
Description of 
Patients 
Intervention 
and Duration 
of Follow Up 
(Mean-
Range) 
Results (subjective measures used unless otherwise 
stated) 
Comments 
Gianino 
1998
49
  
I - Intractable 
spasticity of 
spinal origin 
25 patients 
 
MS 15 
SCI 7 
 
Mean age 39 
(21-70) 
12 month 
follow-up 
available for 
16 patients. 
 
Synchromed 
Ferrans and Powers Quality of life index – no change 
between baseline and 12 months. 
Sickness Impact profile (0-100 scale) improved from 29.7 
to 21.7 p 0.0082. (14/16 patients had improved score).  
Physical subscore 38.5 to 31.0 p=0.001. (13/16 
improved).  Psychological subscore 20.8 to 13.0 
p=0.025.(12/16 improved). 
Subjects identified the following features of their disease 
as important, difficulty in dressing, walking, standing, 
transferring, moderate to severe pain, reduced 
independence, decreased social interaction and stress on 
relationships. 
Use of 2 
measures led 
to 
'questionnaire 
fatigue'.  
Researchers 
felt that 1 year 
follow-up may 
not be enough 
to 
demonstrate 
changes.  
Measures 
used may not 
be very 
sensitive in 
this group. 
Loubser 
1991
74
 
I - Spinal injury, 
severe 
spasticity, failure 
to respond to 
oral treatment, 
response to test 
dose. 
E - Myelography 
showing scarring 
of intrathecal 
space 
7 patients 
 
Spinal injury 
and severe 
spasticity. 
 
Mean age 42 
(22-61) 
Medtronic 
8611H  
16 months (5-
24) 
 
 
3/7 who were previously unable to travel became able to 
take vacations. 
1/7 reported improved sexual function. 
 
Limited 
outcome data 
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Trial, 
Year, 
Review 
Number 
Inclusion (I) 
Exclusion (E) 
Description of 
Patients 
Intervention 
and Duration 
of Follow Up 
(Mean-
Range) 
Results (subjective measures used unless otherwise 
stated) 
Comments 
Loubser 
1996
57
 
I - Spinal injury, 
severe 
spasticity, failure 
to respond to 
oral  treatment, 
response to test 
dose. 
E - psychological 
co-morbidity 
12 patients 
 
Spinal injury 
and severe 
spasticity.  
 
Mean age 43 
(21-63) 
Medtronic 
8611H 
12 months 
 
6 patients with musculoskeletal pain became pain free.   
None of the 9 patients with neurogenic pain became pain 
free. 
Series 
includes 7 
patients from 
previous 
publication. 
Mertens 
1995
53,88
  
I - Severe 
chronic disabling 
spasticity due to 
a spinal lesion.  
Refractory to 
oral treatment, 
Response to test 
dose,  
Favourable 
environment for 
rigorous out-
patient follow-up, 
Age 18-65. 
Cognitive 
capacity to give 
informed 
consent. 
17 patients 
 
5 SCI 
7 MS 
1 Friedrich’s 
Disease 
1 Cervical 
myelopathy 
1 Dorsal 
myelopathy 
1 Syringomyelia 
15 wheelchair 
dependent/ 
bedbound,  
Age 25-61 
Medtronic 
8615 
37.5 months 
(5-69) 
 
Mean functional disability score (composite score 
measuring pain, spasms, wheelchair use, transfers and 
washing/dressing each on a 4 point scale) decreased 
from 13.4 +/-2.7 to 5.8 +/-2.7 (p<0.0001) 
Sitting position, transfers and nursing care became easier 
in all patients. 
1/15 wheelchair bound patients became able to walk with 
crutches. 
2/2 ambulatory patients improved walking distance, one 
of whom became able to walk alone outside his/her 
home. 
9/9 patients with spasm related pain became - pain free. 
1 patient became able to self-catheterise. Urinary urgency 
was ameliorated in 2 patients. 
Functional 
improvement 
was greater in 
paraparetic 
and paraplegic 
patients with 
spinal cord 
injury than in 
tetraplegic 
patients with a 
progressive 
disease. 
 
 61 
 
 
Trial, 
Year, 
Review 
Number 
Inclusion (I) 
Exclusion (E) 
Description of 
Patients 
Intervention 
and Duration 
of Follow Up 
(Mean-
Range) 
Results (subjective measures used unless otherwise 
stated) 
Comments 
Middel 
1997
50
 
I -18yrs+, 
chronic disabling 
spasticity of 
spinal origin 
inhibiting 
personal care, 
sitting, lying and 
transfers 
accompanied by 
pain and 
stiffness, or 
disturbed 
sleeping. 
Insufficient 
response to oral 
treatment.  
Sufficient 
understanding of 
consequences of 
treatment.  
Response to a 
test dose. 
E - Pregnancy, 
supraspinal 
spasticity. 
22 patients 
 
13 MS, 9 SCI 
 
All were non-
ambulatory 
 
Mean age 48  
Placebo 
controlled 
RCT of 
intrathecal 
baclofen for 3 
months.  All 
patients 
received  
intrathecal 
baclofen  
after 3 
months.  Both 
groups were 
followed up 
for 12 months 
after starting 
intrathecal 
baclofen. 
 
Synchromed.  
No significant difference between placebo and 
intervention groups BUT at 3 months the intervention 
group showed modest improvements in the physical and 
psychosocial dimensions of the Sickness Impact Profile 
and the mental health component of the Hopkins 
Symptoms Checklist compared to baseline. 
 
At 1-year follow-up there were modest improvements in 
the physical dimension of the Sickness Impact Profile 
(41.5 to 31.5 – on a 0-100 scale), but not on psychosocial 
aspects of the score. 
Only RCT of 
continuous 
infusion of 
intrathecal 
baclofen. 
 
Failure to 
demonstrate 
significant 
differences in 
placebo and 
intervention 
group, but 
sample size 
may have 
been too 
small. 
 
Statistically 
significant, but 
relatively 
modest 
changes in the 
SIP score 
were seen at  
1 year.  
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Trial, 
Year, 
Review 
Number 
Inclusion (I) 
Exclusion (E) 
Description of 
Patients 
Intervention 
and Duration 
of Follow Up 
(Mean-
Range) 
Results (subjective measures used unless otherwise 
stated) 
Comments 
Nanninga 
1989
58
 
I - Response to 
bolus dose, 
failure to 
respond to oral 
treatment, 
bladder 
dysfunction 
associated with 
spasticity. 
7 patients 
 
6 SCI,  
1 transverse 
myelitis.   
Adults 
Medtronic 
8601 
1–4 years  
 
4 patients who were incontinent between catheterisations 
became continent between catheterisations. 
3 patients with indwelling catheters became able to use 
intermittent catheterisation. 
1 patient who was impossible to catheterise became 
possible to catheterise. 
 
Only bladder 
function 
outcomes 
were 
measured 
Ordia 
1996
55
 
I - Intractable 
spasticity of 
spinal cord 
origin, failed 
medical 
management, 
response to test 
dose  Ashworth 
3 or higher or 
spasm score 2 
or higher. 
E - Pregnancy 
or not using 
birth control, 
baclofen 
allergy. 
59 patients 
 
27 SCI 
26 MS 
2 Familial 
Spastic 
paraparesis 
1 spinal cord 
tumor 
1 cervical 
myelopathy 
1 transverse 
myelitis 
1 Amyotrophic 
lateral sclerosis 
Mean age 42 
yrs. (16-73) 
Medtronic  
42 months 
(23-70) 
 
Reported improvements in ADL, transfers, pain, and 
sleep but in an unspecified number of patients. 
 
4 females able to resume sexual intercourse.  
4 ambulatory patients were able to walk more easily. 
1 wheelchair bound patient became ambulatory.   
Voice was clearer in 4 patients.  
2 unemployed patients became employed.  
The average reduction in bed days was 2.7/patient/yr. 
(measured in 10 patients). 
 
Mainly 
subjective 
outcome 
measures with 
failure to give 
numbers of 
patients 
responding 
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APPENDIX B  STUDIES INCLUDING PATIENTS WITH SPASTICITY OF CEREBRAL ORIGIN 
 
Trial, 
Year, 
Review 
Number 
Inclusion (I) 
Exclusion (E) 
Description of 
Patients 
Intervention 
and Duration 
of Follow Up 
(Mean-
Range) 
 
Results (subjective measures used unless otherwise 
stated) 
Comments 
Albright 
1993
60
 
I - Severe 
spasticity of 
cerebral origin, 
failure to 
respond to oral 
drugs, 
response to 
test dose. 
37 patients 
 
33 CP, 3 TBI, 1 
post 
encephalitis  
 
25 capable of 
self care 
(functional 
group), 22 were 
ambulatory.  
12 incapable of 
self care (non-
functional 
group). 
 
Mean age 14 
(5-27). 
Medtronic 
8611 
23 months (3-
48) 
Self caring patients n=25 
 
76% modest improvement in ADL 
76% improved upper limb function 
40% other benefits such as improved ambulation or 
speech 
1 patient became able to walk with a frame 
2 patients became worse from decreased tone. 
 
 
 
 
 
 
Non-self caring patients with severe disease n=12 
 
None showed a measurable improvement in activities of 
daily living 
7 patient/carers were interviewed 
6/7 reported improved ease of care 
4/7 reported improved ease of dressing 
4/7 reported improved perineal care 
2/7 transfers became more difficult. 
Independence 
improved in 
functional 
group.   
 
Nursing care 
improved in 
non functional 
group. 
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Trial, 
Year, 
Review 
Number 
Inclusion (I) 
Exclusion (E) 
Description of 
Patients 
Intervention 
and Duration 
of Follow Up 
(Mean-
Range) 
 
Results (subjective measures used unless otherwise 
stated) 
Comments 
Armstrong 
1997
89
 
I - 4-18yrs, 
severe 
spasticity 
involving whole 
body and 
interfering with 
daily 
care/function, 
stable 
underlying 
condition, 
response to 
bolus dose 
12 patients 
 
6 CP, 2 TBI, 4 
near drowning.   
 
Mean age 10 
(4-19). 
 
6 Medtronic,  
6 Infusaid  
 
1-5 years 
 
Carer Assessment 
 
9/12 carers reported child as greatly improved. 3/12 as 
somewhat improved. (Areas of improvement included 
improved ease of care, decreased irritability, tolerance to 
handling, more participation in daily activities, weight 
gain). 
High doses 
needed 
 
Benefits 
greatest if 
severe 
extensor 
posturing.  
 
37% failed to 
respond to 
bolus or had 
unwanted 
effect of bolus. 
Becker 
1997
7
 
I - Traumatic 
or Hypoxic 
Brain Injury.  
Spasticity 
interfering with 
nursing 
care/physio-
therapy. 
Response to 
test dose 
18 patients 
Traumatic/ 
Hypoxic Brain 
injury. Mean 
age 41(25-70) 
12 vegetative 
state 
5 severely 
disabled 
1 mildly 
disabled 
12 bedridden 
Medtronic 
8611H  
13-54 months 
6 wheelchair bound patients 
3/6 improved wheelchair mobility. 
 
 
 
 
12 bedbound patients in a vegetative state. 
8/12 became able to sit for some of the day. 
 
Ease of care improved in all patients. 
11 patients had chronic decubital ulcers - 5 healed, 5 
improved. 
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Trial, 
Year, 
Review 
Number 
Inclusion (I) 
Exclusion (E) 
Description of 
Patients 
Intervention 
and Duration 
of Follow Up 
(Mean-
Range) 
 
Results (subjective measures used unless otherwise 
stated) 
Comments 
Concalves 
1994
61
 
I - Severe 
spasticity of 
supraspinal 
origin, 
unresponsive 
to oral drugs, 
response to 
bolus dose. 
11 patients 
 
8 TBI  
3 CP 
Mean age 29 
(13-52) 
Medtronic 
3.2 yrs (1-6) 
Of 4 wheelchair-bound patients, 1 developed 
handicapped walking. 
Of 2 patients with bladder dysfunction both developed 
improved control. 
Of 4 with no speech, 1 developed unintelligible speech 
and 1 developed dysarthria. 
Conscious level improved in one patient. 
2/11 pump 
explanted 
Gerszten 
1997
62
 
I - Moderate or 
severe 
spasticity of 
cerebral origin.  
Response to 
test dose. 
 
24 patients 
 
21 CP.  
Mean age 18 
years (9-30) 
Medtronic 
52 months 
(12-88) 
 
Of 7 patients who were able to walk only in therapy 
sessions, 4 became able to walk at home, 2 lost the 
ability to walk. 
 
 
 
Of 6 patients who were only able to walk at home, 2 
became able to walk in the community. 
 
 
Of 8 patients who were able to walk in the community, 1 
lost the ability to walk in the community. 
 
Overall 37% showed an improvement in ambulatory 
category and 12.5% showed a deterioration. 
Overall Function (subjective assessment of endurance, 
ease of transfers, and activities of daily living) improved in 
20 patients, worsened in 2, and was unchanged in 2 
patients. 
3/19 patients who used ankle orthoses were able to stop 
using them. 
1 of only a few 
studies to 
examine effect 
on ambulation. 
 
Moderate 
benefits to 
ambulation 
achieved in 
some.  
 
Deterioration 
in others. 
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Trial, 
Year, 
Review 
Number 
Inclusion (I) 
Exclusion (E) 
Description of 
Patients 
Intervention 
and Duration 
of Follow Up 
(Mean-
Range) 
 
Results (subjective measures used unless otherwise 
stated) 
Comments 
Saltuari 
1992
90
 
I - Severe 
spasticity of 
supraspinal 
origin, 
unresponsive 
to oral drugs, 
and physical 
therapy, 
response to 
bolus dose, 
informed 
consent from 
patients or 
carers. 
E - Patients 
with poor 
prognosis 
9 patients 
 
6 TBI  
1 hypoxic brain 
injury 
1 Little’s 
disease 
1 hereditary 
spastic 
paraparesis 
Mean age 23 
(14-46). 
Medtronic 
8611H 
 
9 (11 days-28 
months) 
1 patient became able to speak. 
1 patient became able to climb stairs without help. 
2 patients became continent. 
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 APPENDIX C  STUDIES INCLUDING PATIENTS WITH SPASTICITY OF SPINAL ORIGIN AND PATIENTS WITH SPASTICITY OF 
CEREBRAL ORIGIN 
 
Trial, 
Year, 
Review 
Number 
Inclusion (I) 
Exclusion (E) 
Description of 
Patients 
Intervention 
and Duration 
of Follow Up 
(Mean-
Range) 
Results (subjective measures used unless otherwise 
stated) 
Comments 
Becker 
1995
66
 
I - Severe 
disabling 
spasticity not 
responsive to 
oral treatment 
or physical 
therapy, 
responsive to 
test dose.  
Age 18+yrs 
E - Substance 
misuse. 
Psychiatric 
problems. 
9 patients 
 
6 MS, 2 SCI, 
1 TBI. 
Non-ambulatory  
Mean age 34 
(20-56) 
MEDTRONIC 
27 months 
(13-47) 
 
 
NURSING ASSESSMENT  
Major improvement  in transfers 8/9, pain control 5/9, 
nursing care 8/9, skin integrity 6/9 
Patient satisfaction in 6 MS patients (1-5 score) – 
Improvement in score = Transfers 3.5 , Seating 3, 
Personal hygiene 2.8, sleeping 2.9, mental functioning 
1.8, pain 2.7, spasticity 2.3, skin condition 1.3. 
Place of residence.  3 patients who were hospitalised 
became able to live in the community (1 in a group 
home).  Of 3 patients who lived in a chronic care 
institution, 2 became able to live in a group home, 1 
moved to hospital.  All 3 patients who lived at home 
remained at home. 
Hospital days - average decrease in hospital days 41 
days per patient per year. 
 
Multi -
disciplinary 
team approach 
necessary. 
 
Careful patient 
selection  
necessary. 
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Trial, 
Year, 
Review 
Number 
Inclusion (I) 
Exclusion (E) 
Description of 
Patients 
Intervention 
and Duration 
of Follow Up 
(Mean-
Range) 
Results (subjective measures used unless otherwise 
stated) 
Comments 
Broseta 
1989
68
 
I - Severe 
spasticity 
caused by 
brain or spinal 
cord injury, 
resistant to 
oral 
medication, 
positive 
response to 
bolus dose. 
14 patients 
 
5 SCI, 4 MS  
4 TBI, 1 CP 
 
7 wheelchair-
bound /bed-
bound  
7 ambulatory.  
 
Mean age 45 
(15-62). 
Medtronic 
pump 11 
months (3-22) 
 
Overall outcome considered excellent in 5 patients, good 
in 4, fair in 3, poor in 2.   
 
5/9 with bladder dysfunction had improved function. 
 
9/10 with pain became pain free. 
 
1 bedridden patient became able to walk with canes.   
 
1/7 ambulatory patients improved walking ability. 
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Trial, 
Year, 
Review 
Number 
Inclusion (I) 
Exclusion (E) 
Description of 
Patients 
Intervention 
and Duration 
of Follow Up 
(Mean-
Range) 
Results (subjective measures used unless otherwise 
stated) 
Comments 
Lazorthes 
1990
69
 
I - Severe 
debilitating 
spasticity. 
Unresponsive 
to oral 
treatment. 
Respond to 
test dose.  
Informed 
consent. 
Available for 
rigorous follow 
up. 
E - Bedsores 
or skin lesions 
which would 
interfere with 
pump 
implantation or 
aggravate 
spasticity.  
Urinary tract 
infections. 
18 patients  
 
6 MS 
7 spinal trauma 
1 spinal 
ischaemia 
1 transverse 
myelitis 
1 cerebral palsy 
1 brain trauma 
1 ischemic 
cerebral lesion 
Mean age 39 
(1-70) 
18 months (4-
43) 
 
1
st
 6 patients 
had baclofen 
delivered 
through 
access port. 
Remainder 
had Medtronic 
pump. 
Modified Davis and Gray scale for evaluation of motor 
performance (> 3 = large improvement, 1-3 = moderate 
improvement, 0 = no improvement). 
3/18 large improvement in function 
9/18 moderate improvement 
6/18 no improvement in function. 
 
14/16 resolution of painful spasms. 
Functional improvement was much greater in patients 
with traumatic lesions than in those with MS although 
both groups had reduction in spasticity and improvement 
in ease of nursing care.  In bedridden patients the 
improvement was limited to reduction of spasticity and 
improved ease of nursing care. 
3/12 Medtronic 
pumps were 
discontinued. 
6/6 access 
ports were 
discontinued. 
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Trial, 
Year, 
Review 
Number 
Inclusion (I) 
Exclusion (E) 
Description of 
Patients 
Intervention 
and Duration 
of Follow Up 
(Mean-
Range) 
Results (subjective measures used unless otherwise 
stated) 
Comments 
Nance 
1995
8
 
I - Spasticity 
unremitting for 
12 months, 
satisfactory 
failed oral 
treatment.  
Response to 
test dose. 
 
7 patients 
 
2 MS, 5 SCI 
 
 
Mean age 38.7 
 
All wheelchair 
users 
 
24-41 months 
4 Medtronic  
3 Infusaid 
No statistically significant change in bladder or respiratory 
function. 
All patients reported marked improvement in comfort and 
ADL: e.g. 1 regained ability to transfer from wheelchair 
independently; 1 able to go outside having been 
previously housebound; 2 experienced healing of chronic 
leg ulcerations. 
2 patients able to reduce requirement for personal 
attendant service. 
140 patients 
referred to unit. 
Treatment of 
aggravating 
factors or 
optimising oral 
treatment  
improved 
spasticity in 
130.  
Ochs 
1996
64
 
I - Severe, 
disabling 
spasticity, 
resistant to 
oral treatment, 
stable or 
slowly 
progressive 
disease or wee 
diagnosed 
disease, no 
contra-
indications, 
response to 
bolus dose. 
70 patients 
 
59 MS, 4 SCI 
4 Myelopathy 
3 Brain injury 
Age 21-71 
6 month 
follow-up 
22 Infusaid 
48 Medtronic 
Of 38 bed-bound patients, 22 became able to use 
wheelchair. 
Of 27 wheelchair users who could not walk, 1 became 
able to walk with crutches. 
4/29 wheelchair users became able to stand. 
8/12 patients who required major help in dressing 
required only a little help in dressing 6 months after CIBI. 
1/4 patients who required a little help became able to 
dress without help. 
2/9 who required help became able to eat alone. 
20/22 patients rated outcome as good or excellent. 
Patients in the 
late stages of 
chronic illness 
(MS) or 
generalised 
cerebral deficits 
(head trauma, 
intracerebral 
haemmorhage) 
had benefit 
limited to 
improved ease 
of care. 
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Trial, 
Year, 
Review 
Number 
Inclusion (I) 
Exclusion (E) 
Description of 
Patients 
Intervention 
and Duration 
of Follow Up 
(Mean-
Range) 
Results (subjective measures used unless otherwise 
stated) 
Comments 
Parke 
1989
70
 
I - Failure to 
respond to oral 
treatment, 
response to 
test doses. 
8 patients 
 
4  SCI, 4 MS 
Mean age 38 
(22-61) 
6 months 
Medtronic 
8611H 
Patient Evaluation Conference System used to measure 
level of dependence.   
4 patients were classified as being dependent on others 
for bladder function, 2 of these became independent.   
7 patients were described as being dependent on others 
for feeding and hygiene, 5 became independent.   
3 patients had skin integrity problems that resolved 
following treatment.   
1 patient became able to drive.   
1 patient with pain became pain free.  
 
Patterson 
1994
52
 
I - Severe 
spasticity, 
failure to 
respond to oral 
treatment, 
response to 
test dose. 
21 patients 
 
15 MS, 3 SCI,  
1 CP,  
1 Syringo-
myelia,  
1 Friedrich’s 
Ataxia,  
1 Transverse 
myelitis 
Non-ambulatory 
 
Mean age 46 
(24-67) 
9-79 months 
Cordis-Secor 
No change in Barthel Index in any patients 
 
16/21 improved ability to sit 
16/21 improved  nursing care 
  2/21 improved social life 
  2/21 became able to drive 
 
Barthel index 
may not be 
sensitive to 
change in this 
group. 
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Trial, 
Year, 
Review 
Number 
Inclusion (I) 
Exclusion (E) 
Description of 
Patients 
Intervention 
and Duration 
of Follow Up 
(Mean-
Range) 
Results (subjective measures used unless otherwise 
stated) 
Comments 
Penn 
1987
67
 
I - Severe 
spasticity, 
failure to 
respond to oral 
drugs, 
response to 
test dose. 
7 patients 
 
SCI and MS 
 
Mean Age 37 
(19-54) 
20 months 
(11-24) 
Medtronic 
8601 
Of 5 non-ambulatory patients, 2 became able to walk with 
long leg braces and crutches 
Of 2 patients who were previously ambulatory, 1 became 
non-ambulatory 
3/7 patients returned to work 
4/4 incontinent patients became continent 
1 patient who was previously unable to self catheterise 
became able to do this. 
All reported improved sleep. 
 
 
Sahuquillo 
1991
72
 
I - Stable 
neurological 
condition 
-Severe 
spasticity 
refractory to 
oral drugs 
-Normal CSF 
circulation 
-Informed 
consent 
-Response to 
test dose 
9 patients 
 
6 SCI,  
1 cervical 
myelopathy,  
1 cervical 
meningioma 
1 shunt 
malfunction 
leading to 
cerebral 
damage.   
Mean age 33 
(12-65) 
8 months  
(5-35) 
 
 
Secor 
resevoir 
 
 
8/8 patients with spasm related pain had relief 
No other functional or quality of life indicators were 
reported. 
 
Limited 
outcome data 
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Trial, 
Year, 
Review 
Number 
Inclusion (I) 
Exclusion (E) 
Description of 
Patients 
Intervention 
and Duration 
of Follow Up 
(Mean-
Range) 
Results (subjective measures used unless otherwise 
stated) 
Comments 
Steers 
1992
91
 
I - Severe 
spasticity, 
voiding 
problems, 
failure to 
respond to oral 
drugs, 
response to 
test dose. 
10 patients 
 
5 SCI, 1 MS 
1 Syringomyelia 
3 Hereditary 
spastic 
paraplegia 
Mean age 36 
(24-61) 
18 months 
(12-23) 
Medtronic 
Of 3 patients with indwelling catheters – 2 minimised 
leakage around catheter, one converted to intermittent 
self catheterisation.   
Of 4 patients with voluntary voiding, 4 noted decreased 
nocturia from an average of 3.1 times per night to 0.8 
times per night. 
 
Only urinary 
functional 
outcomes 
measured. 
Stewart-
Wynne 
1991
63
 
I - Failure to 
respond to oral 
treatment - 
response to 
test dose. 
6 patients 
 
2 SCI, 3 MS, 1 
Motor Neurone 
Disease.   
 
Adult patients – 
ages not stated 
24 months  
(6-42) 
Infusaid pump 
No change in dependency levels but all aspects of daily 
care were said to be performed more easily. 
ADLs said to improve in all patients but no data provided.  
All patients became able to sit in a wheelchair and lie 
comfortably in bed at night. 
Mainly 
subjective 
outcome 
measures. 
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Trial, 
Year, 
Review 
Number 
Inclusion (I) 
Exclusion (E) 
Description of 
Patients 
Intervention 
and Duration 
of Follow Up 
(Mean-
Range) 
Results (subjective measures used unless otherwise 
stated) 
Comments 
Zierski 
1988
65
 
I - Severe 
spasticity not 
responding to 
oral drugs. 
Adequate 
response to 
test dose. 
E - Test dose 
leading to loss 
of muscle tone 
sufficient to 
impair 
ambulation. 
37 patients 
 
SCI, MS, CP, 
Traumatic/ 
Hypoxic brain 
injury 
 
 
Age range 2-71 
years 
 
10 months  
(2-28) 
Infusaid pump 
14/20 bedridden patients became able to sit in a 
wheelchair for several hours each day.  The nursing care 
of the remaining 6 bedridden patients became easier. 
10/12 wheelchair bound patients improved their mobility.  
3/5 ambulatory patients improved walking ability. 
13/17 with spasm-related pain became pain-free. 
On a 1-4 scale (1 very good, 4 poor) carers rated the 
outcome as 1.37 (mean).  
Physicians rated the outcome as 1.32 (mean). 
Many outcomes 
were subjective. 
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APPENDIX D REFERRAL CRITERIA FOR CHILDREN WITH SPASTICITY OF 
CEREBRAL ORIGIN (CP) 
 
Michael Vloeberghs  
Senior Lecturer 
Consultant Paediatric Neurosurgeon 
University of Nottingham 
 
Introduction: 
These sub-groups represent the CP children referred to the Neurosurgery Department at 
Queen's Medical Centre. The following classification is proposed merely for the purposes of 
considering CIBI treatment. More standardisation of results is required in order to quantify 
results and determine positive or negative outcomes.  
 
Sub-groups in CP:  
 
1. Spastic tetraplegics: These severely disabled children suffer from increasing nursing 
problems ranging from positional disability e.g. being unable to sit in a wheelchair, to 
lying flat in bed, etc. 
 
2. Cognitively disabled mobiles: These children are in special schools, may be able to 
mobilize with help and are situated on the borderline of the previous group. 
 
3. Cognitively intact mobiles: These children are in mainstream schools and perform 
normally, but are held back by their physical disability.   
 
The aims of CIBI treatment are different for each group.  
 
Group 1. CIBI aims to improve quality of life and prevent further disability due to 
orthopaedic deformity. 
Group 2. As a borderline of group 1, the aim is to improve quality of life rather than to 
improve mobility. Nursing can be made easier e.g. by decreasing adductor 
tone, but marked improvement of gait is unrealistic because of the cognitive 
disability, which makes compliance with post-procedure physiotherapy 
difficult. 
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Group 3. The expectations are very high in this group and a negotiated settlement is 
necessary with the child and its parents prior to the procedure. This group 
represents a spectrum of children who may be wheelchair bound, partially 
mobile or purely gait impaired. The aim of CIBI is to improve mobility and 
increase social and educational performance due to the net effect of CIBI on 
the upper limbs.  
 
Referral criteria: 
 
At present Mr Vloeberghs is confronted with an entire spectrum of children in whom 
spasticity has been treated conservatively. Only the failures of the conservative approach 
are brought to his attention, but this does give an overview of the need and demand for 
CIBI. The following criteria are valid for all groups described above. 
 
1. The patient must be over four years old, because of the very limited data on CIBI in 
patients under four years old and the technical difficulty of inserting a drug delivery 
system in this age group. 
2. Immobile children with CP in which the spasticity is causing increasing deformity or 
nursing demands, for example in association with positional problems. Conventional 
means will already have been attempted, e.g. physiotherapy, botulinum toxin, 
orthopaedic interventions, orthoses. The evidence of benefit of CIBI is best in this type of 
problem but more evidence is required. Therefore, it is recommended that all children 
receiving CIBI should be part of a national research study documenting changes with 
this intervention.  
3. Severe gait disturbance in association with spasticity, with or without upper limb 
involvement in a child with severe learning difficulties.  Evidence for the benefit of CIBI in 
these children is very sparse. All children receiving CIBI must be part of a national multi-
centre controlled trial documenting the benefit of this intervention.  
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APPENDIX E  BREAKDOWN OF COSTS RELATED TO CIBI 
 
 Cost Element Low Estimate High Estimate 
Prescreening 1x new out-patient appointment with neurosurgeon  £330.00  £556.00 
Prescreening total   £330.00  £556.00 
Test dose 1x procedure A542 injection of therapeutic 
substance (minor) 
 £163.00  £163.00 
 1x lumbar puncture  £189.00  £189.00 
 1x lumbar catheter  £20.00  £30.00 
 Ward care/ accommodation (E39) – assuming 2 
night in-patient stay. 
 £490.00  £1,102.00 
 Cost of drug  £60.00  £70.00 
  Physio assessment 1/2 hour  £20.00  £20.00 
Test dose total   £942.00  £1,574.00 
Pump implantation Cost of pump  £6,768.00  £6,768.00 
 Cost of catheter  £229.13  £229.13 
 1x procedure - implant pump (code) - major 
procedure A3300 
 £509.00  £509.00 
 Ward care/accommodation (E39) – assuming 5 
night in-patient stay. 
 £1,225.00  £2,755.00 
Pump implantation total   £8,731.13  £10,261.13 
Other costs Laptop Free - on loan Free - on loan 
 Transport costs  £50.00  £100.00 
 Education requirement not known  not known 
Tests, pathology, radiology, microbiology (all)  £500.00  £500.00 
Other costs total   £550.00  £600.00 
Aftercare (post-op) Refill kit  £22.00  £22.00 
 Drug costs 2000 mcmgs baclofen  £59.00  £72.00 
 Follow-up out-patient appointment / PIU  £50.00  £50.00 
 Physio assistant 1/2 hour per day  £10.00  £10.00 
Aftercare (post-op) total   £141.00  £154.00 
Pump replacement 
procedure 
1x procedure  £509.00  £509.00 
 Ward care/accomodation (E39) - range of nights 
stay 
 £1,225.00  £2,755.00 
 Pump (latest cost from Medtronic)  £6,768.00  £6,768.00 
 Catheter  £229.13  £229.13 
 Drugs  £59.00  £72.00 
Pump replacement 
procedure total 
  £8,790.13  £10,333.13 
    
Total costs for CIBI implantation - prescreening, test dose, pump 
implantation, other costs and tests 
 £10,553.13  £12,991.13 
    
Mid point estimate   £11,772.13  
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APPENDIX F  SUMMARY OF COST PAPERS RELATING TO CIBI 
Study Patient 
Characteristics  
Method Results Savings and Comments 
Nance et 
al. (1995)
8
 
6 patients in 
costing study. 
 
SCI or MS 
Hospital 
admissions 
where spasticity 
was causally 
related to 
spasticity 2 
years prior to 
treatment, 2 
years post 
treatment. 
Prior 2 years: 376 in-patient hospital 
days (range: 0-186, average 63 days).  
Post 2 years: 136 in-patient days 
(range: 11-36, average 23 days), none 
of which was due to spasticity. All 
admissions post CIBI were related to 
screening, implantation, treatment of 
problems related to the intrathecal drug 
delivery devices and problems related 
to marked reduction in muscle tone.  
The authors report average net savings of CDN 
$25,250 per patient, taking account of the cost of pump 
and hospital days (average cost per in-patient day 
$813). The authors consider the treatment to be cost-
effective. 
 
Using UK costs of £211 per in-patient day, there would 
be savings of £8,440 over 2 years in reductions of 
hospital days. This would balance the cost of the pump. 
 
The number of days used within the post CIBI years 
may be over-estimated due to use of placebo days in 
the screening phase.  
 
2 patients reported ability to decrease personal 
attendant services and one patient obtained 
employment following CIBI. 2 patients had skin ulcers 
which healed following CIBI. 
 
Only 6 patients were included within the costing 
exercise. 
Becker et 
al. 
(1995)
66
 
9 patients  
 
6 MS, 2 cervical 
SCI and 1 head 
injury. 
Hospital acute 
care 
hospitalisation 
costs 1 year 
prior and one 
year post 
implantation. 
Prior to implantation: 755 acute 
hospital days (range: 0-319, average 
84 days). 
Year of implantation: 259 days (range: 
10-48, average 29 days). 
 
Based on cost of hospital stay of $570 per day, 
reductions in hospital days give average saving of 
$31,000 per patient (this does not include pump and 
implant).  
 
Using UK costs of £211 per in-patient day, there would 
be savings of £11,660 within the first year in reductions 
of hospital days. This would balance the cost of the 
pump. 
 
At time of implantation, 6 of the 9 patients were 
institutionalised in either chronic or acute care hospitals 
due to problems managing their spasticity. Following 
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Study Patient 
Characteristics  
Method Results Savings and Comments 
CIBI 3 patients were discharged after prolonged 
hospitalisation, 2 back home and 1 to a group home.  
 
Savings are likely to be under-estimated as 2 patients 
were in chronic care institutions prior to implantation 
and, thus, would not have required acute care. 
Authors conclude CIBI to be beneficial in terms of 
nursing assessment, patient satisfaction and cost-
effectiveness. 
Ordia et 
al.  
(1996)
55
  
10 patients  
 
Spasticity of 
spinal cord origin, 
MS or SCI 
 
59 patients in total 
had pump 
implant, but only 
first 10 were 
included in cost 
study. 
Number of bed 
days used for 1 
year prior and 1 
year following 
implantation. 
Hospitalisations 
were all cause 
and not 
specifically 
related to 
spasticity. 
Prior to implantation: 95 bed days. 
Post implantation: 68 bed days. 
 i.e. 2.7 days per patient saved for 
general hospitalisations in 1 year. 
 
Also 58 days used for screening and 
implantation, i.e. 5.8 days used per 
patient for the screening and 
implantation. 
This study does not report the proportion of days that 
are related to spasticity and, thus, may include 
admissions for unrelated causes. Similarly, there is no 
information as to the number of post implant bed days 
that are due to complications from the procedure. 
The number of bed days reported is low as patients 
who received acute rehabilitation less than 1 year prior 
to surgery were excluded from cost study.  
 
Authors concluded CIBI to be a cost-effective method 
for treatment of severe intractable spinal spasticity. 
However, this was based upon a average cost of 
$2,500 per day. 
Postma et 
al. 
(1999)
81
  
Case control 
study –  
18 patients 
undergoing CIBI, 
(11 MS, 7 SCI) 
15 match patients 
of similar age, sex 
and diagnosis (9 
MS, 6 SCI). 
Comparison of 
the number of 
days in hospital 
between groups 
1 year prior to 
implantation and 
1 year following 
implantation. 
Average number of hospital days in 
year of implant in treated group was 
31.5 days; 9.9 in the test phase, 12.3 
for the implantation phase and 8.4 
days resulting from complications. 
This was in comparison to 18.7 days 
for the matched patients.  
In the year following implantation no 
significant difference was found.  
 
A calculation of the average direct costs that would be 
likely to occur in a non-experimental situation was made 
in this study. For this analysis only 2 days were 
allocated to the test phase, 10.3 for the implantation 
phase and again, 8.4 days for complications. If this had 
been the case, the average number of days for the 
treated group would have been 20.7, that is only 2 
additional days in comparison to the matched group. 
 
For the non-experimental situation, the total average 
cost of selection, testing, implantation and medical 
follow up amounted to US$28,473 per patient for the 
first year. Full break down given in paper. 
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APPENDIX G   INDEX OF HEALTH RELATED QUALITY OF LIFE 
 
The IHQL provides a broad and sensitive measure of social, psychological and physical 
functioning and is designed to be applicable across all diagnostic groups. Using this 
instrument, it is possible to derive an assessment of health status on a single 
unidimensional scale. 
 
The IHQL is derived from the original two-dimensional Rosser Index based on the 
dimensions of disability and distress.  In this scale, distress is separated into physical and 
emotional components, to give three dimensions (disability, physical distress and emotional 
distress). 
 
Valuations for the 175 composite health states were obtained using standard gamble for 
states of 1 year duration.  No assessment has yet been made of the test-retest reliability of 
the scaling method, the stability of ratings over time, or the consensus of the values 
obtained from different sample groups. 
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3-Dimensional Classification 
Disability 
D1: No physical disability; perfectly mobile and physically active; able to perform all self-
care and role functions. 
D2: Slight social disability, e.g. having a slight cold.  No limitations with physical ability, self-
care or mobility, but some role functions slightly impaired by social disability. 
D3: Slight physical disability.  Able to get round house and community, but unable to 
perform heavy physical tasks.  Role functions slightly limited by physical disability.  Able 
to perform all self-care activities. 
D4: Able to get round house and do lighter physical work.  Some difficulty in getting 
community due to weakness or other physical limitations.  Can perform all self-care 
activities.  Ability to perform role functions limited. 
D5: Difficulty in getting around house, can only go out with assistance.  Major physical 
limitations, e.g. can only do light work.  Can perform most self-care activities, but need 
help getting in and out of the bath.  Limited ability to perform role functions. 
D6: Confined to a chair, therefore, can only get out with assistance.  Can only do the 
lightest of tasks, e.g. switch on the TV.  Can feed self, but needs help with all other 
health care activities.  Very limited ability to perform role functions. 
D7: Confined to bed.  Needs help with all self-care activities.  Minimal ability to perform role 
functions. 
D8: Unconscious. 
 
Discomfort (Physical) 
P1: No pain. 
P2: Slight pain:  (a) occasionally, (b) frequently, (c) almost all the time. 
P3: Moderate pain: (a) occasionally, (b) frequently, (c) almost all the time. 
P4: Severe pain:  (a) occasionally, (b) frequently, (c) almost all the time. 
P5: Agonising pain:(a) occasionally, (b) frequently, (c) almost all the time. 
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Distress (Emotional) 
E1: No distress: very happy and relaxed almost all of the time. 
E2: 
 
Slight distress : happy and relaxed most of the time, but anxious and depressed 
some of the time. 
E3: 
 
Moderate distress: anxious and depressed most of the time, but happy and relaxed 
some of the time. 
E4: Severe distress: very anxious and depressed almost all of the time. 
E5: Extremely depressed: actively suicidal. 
 
Composite state valuations (0-1 scale of values) 
  E1 E2 E3 E4 E5 
P1 D1 1.000 0.970 0.894 0.791 0.643 
 D2 0.990 0.960 0.884 0.781 0.632 
 D3 0.971 0.940 0.864 0.762 0.614 
 D4 0.946 0.917 0.840 0.738 0.590 
 D5 0.917 0.887 0.811 0.710 0.561 
 D6 0.885 0.855 0.780 0.678 0.530 
 D7 0.838 0.804 0.729 0.628 0.481 
P2 D1 0.944 0.915 0.838 0.736 0.588 
 D2 0.934 0.904 0.828 0.726 0.578 
 D3 0.915 0.885 0.810 0.708 0.559 
 D4 0.891 0.861 0.785 0.684 0.537 
 D5 0.861 0.831 0.756 0.654 0.508 
 D6 0.829 0.799 0.724 0.623 0.477 
 D7 0.779 0.750 0.675 0.574 0.427 
P3 D1 0.867 0.837 0.761 0.660 0.513 
 D2 0.857 0.827 0.751 0.650 0.503 
 D3 0.837 0.808 0.732 0.631 0.485 
 D4 0.814 0.784 0.709 0.608 0.461 
 D5 0.785 0.755 0.680 0.579 0.433 
 D6 0.753 0.723 0.648 0.548 0.402 
 D7 0.702 0.674 0.598 0.498 0.353 
P4 D1 0.714 0.685 0.610 0.510 0.365 
 D2 0.703 0.675 0.599 0.499 0.354 
 D3 0.685 0.656 0.581 0.481 0.337 
 D4 0.661 0.632 0.557 0.458 0.313 
 D5 0.632 0.604 0.528 0.429 0.285 
 D6 0.601 0.572 0.497 0.399 0.254 
 D7 0.551 0.522 0.449 0.350 0.207 
P5 D1 0.468 0.439 0.365 0.267 0.125 
 D2 0.457 0.428 0.355 0.257 0.114 
 D3 0.439 0.410 0.337 0.239 0.097 
 D4 0.416 0.387 0.314 0.216 0.074 
 D5 0.387 0.358 0.285 0.188 0.047 
 D6 0.356 0.327 0.255 0.159 0.017 
 D7 0.308 0.279 0.207 0.111 -0.030 
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